RNAi Based Therapeutics and Novel RNA Bioengineering Technologies

Gavin M. Traber and Ai-Ming Yu*.

Department of Biochemistry and Molecular Medicine, University of California (UC) Davis School of Medicine, Sacramento, California, 95817 (G. M. T.; A-M. Y.)
Running title: RNAi Therapeutics and Novel RNA Bioengineering Technologies

* Corresponding author: Ai-Ming Yu, Department of Biochemistry and Molecular Medicine, University of California (UC) Davis, School of Medicine, 2700 Stockton Boulevard, Suite 2130, Sacramento, CA 95817; Phone: +1 (916) 734-4848; email: aimyu@ucdavis.edu

Number of text pages: 52
Number of tables: 4
Number of figures: 3
Number of references: 272
Number of words in the Abstract: 244
Number of words in the Introduction: 668

List of abbreviations used in the paper:
3'UTR; 3' untranslated region;
A, adenosine;
ACC, adrenocortical carcinoma;
Af, adenine 2'-F ribonucleoside;
AGO2, argonaut 2 endonuclease;
AGT, alanine-glycolate aminotransferase;
AHF, acute heart failure;
AHP, acute hepatic porphyria;
AKI, acute kidney injury;
ALAS1, aminolevulinate synthase 1;
Am, adenine 2'-OMe ribonucleoside;
AMD, age-related Macular Degeneration;
Anti-miR, antisense oligonucleotides targeting miRNA;
ARBCP, abnormal red blood cell production;
ARF, acute Renal Failure;
ASGR1, asialoglycoprotein Receptor 1;
ASO, antisense oligonucleotide;
ASCVD, atherosclerotic cardiovascular disease;
Au, gold;
BioRNA or BERA, bioengineer RNA agent;
btRNA, bacterial tRNA;
C, cytidine;
CDS, coding DNA sequence or protein coding region;
Cf, cytosine 2'-F ribonucleoside;
CHF, chronic heart failure;
circRNA, circular RNA;
Ckip-1, casein kinase-2 interacting protein-1;
Cm, cytosine 2'-OMe ribonucleoside;
CMD, cardiometabolic disease;
CNV, choroidal neovascularization;
DED, dry eye disease;
DGCR8, DiGeorge Syndrome Critical Region 8;
DGF, delayed graft function;
DME, diabetic macular edema;
DR, diabetic retinopathy;
DSPC, distearoylphosphatidylcholine;
dsRNA, double-stranded RNA;
(DSS)$_6$, aspartate, serine and serine;
dT, thymidine;
EGFR, epidermal growth factor receptor;
ELVd, eggplant latent viroid;
ELV, exosome-like vesicle;
ESC, enhanced stability chemistry;
Fe$_3$O$_4$, iron(III) oxide;
FDA, United States Food and Drug Administration;
FPLC, fast protein liquid chromatography;
G, guanosine;
GalNAc, N-acetylgalactosamine;
Gf, guanine 2'-F ribonucleoside;
Gm, guanine 2'-OMe ribonucleoside;
GO, glycolate oxidase;
GoF, gain-of-function;
hATTR, hereditary transthyretin-mediated amyloidosis;
HAO1, hydroxyacid oxidase 1;
HCC, hepatocellular carcinoma;
HCV, hepatitis C virus;
HPV, human papillomavirus;
HeFH, heterozygous familial hypercholesterolemia;
htRNA, humanized tRNA;
iv, intravenous;
IVT, in vitro transcription;
L96, tri-N-acetylgalactosamine;
LDH, lactate dehydrogenase;
LDL-C, low-density lipoprotein cholesterol;
LDL-R, low-density lipoprotein receptor;
LNA, locked nucleic acid;
LNP, lipid nanoparticle;
Lpp, lipoprotein;
MI, Myocardial Infarction;
miRISC, microRNA in RNA-induced silencing complex;
microRNA or miR, microRNA;
MM, multiple myeloma;
MPM, malignant pleural mesothelioma;
mRNA, messenger RNA;
NAFLD, nonalcoholic fatty liver disease;
NAION, non-arteritic anterior ischemic optic neuropathy;
NASH, non-alcoholic Steatohepatitis;
ncRNA, non-coding RNA;
NP, nanoparticle;
NSCLC, non-small cell lung cancer;
OLE, open-label extension;
p19, plant tombusvirus encoded 19 kD protein;
PAA, polyacrylic acid;
PACE, poly(amine-co-ester);
PAD, peripheral arterial disease;
PCSK9, proprotein convertase subtilisin/kexin type 9;
PDAC, pancreatic ductal adenocarcinoma;
PDC, pancreatic ductal carcinoma;
P EG, polyethylene glycol;
PEI, polyethylenimine;
PH1, primary hyperoxaluria type 1;
PH2, primary hyperoxaluria type 2;
piRNA, P-Element induced wimpy testis-interaction RNA;
PIWP, P-Element induced wimpy testis;
PKD, polycystic kidney disease;
PLC, primary liver cancer;
pre-miRNA, pre-microRNA;
pri-miRNA, primary microRNA;
PS, phosphorothioate;
PTX/CBP, paclitaxel plus carboplatin;
RAN, GTP-binding nuclear protein for pre-miRNA transport;
RCC, renal cell carcinoma;
RISC, RNA-binding silencing complex;
RNAi, RNA interference;
rRNA, ribosomal RNA;
s, phosphorothioate;
sc, subcutaneous;
SCLC, small cell lung cancer;
shRNA, short hairpin RNA;
siRISC, small interfering RNA in RNA-induced silencing complex;
siRNA, small interfering RNA;
snoRNA, small nucleolar RNA;
sRNA, small RNA;
ssRNA, single-stranded RNA;
TMTME, too many targets for miRNA effect;
TRBP, transactivating response RNA-binding protein;
tRNA, transfer RNA;
tRF, tRNA-derived RNA fragments;
TRPV1, transient receptor potential cation channel subfamily V member 1;
TTR, transthyretin;
U, uracil;
Uf, uracil 2'-F ribonucleoside;
Um, uracil 2'-OMe ribonucleoside.
Abstract

RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNA) and exogenous small interfering RNAs (siRNA), converge into RNA-induced silencing complexes to achieve post-transcriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the United States Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biological activity away from their natural equivalents. Novel technologies in development today seek to utilize intact cells to yield true biological RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiological and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran), as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biological RNAi agents for research and development.
Significance Statement

In our review, we summarize the major concepts of RNA interferenace (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of FDA-approved RNAi medications and those siRNAs and miRNA-based therapeutics entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.
1. Introduction

Genome-derived functional microRNA (miRNA) was initially elucidated in *Caenorhabditis elegans* during the characterization of the *lin-4* gene encoding a small RNA (sRNA) with antisense complementarity and the capacity for posttranslational regulation of target gene *lin-14* (Lee et al., 1993; Wightman et al., 1993). Later on, miRNAs were identified as a superfamily of conserved and functional noncoding RNAs (ncRNAs) that are present in a wide range of animal species (Pasquinelli et al., 2000; Li et al., 2010), including humans (Friedlander et al., 2014). Since then, the development of RNA interference (RNAi) technology (Napoli et al., 1990; Fire et al., 1998) has offered new routes for the studies of reverse genetics, specific gene expression and regulation, and targeted therapy with the potential to study, manipulate, and achieve control of disease. In particular, RNAi is accomplished through the interactions of sRNA molecules, namely small interfering RNAs (siRNAs) and miRNA, with functions that lie outside the confines of the central dogma of molecular biology (Sen and Blau, 2006; Setten et al., 2019). Aside from miRNAs and siRNAs, a third major class of RNAi molecules exist, termed P-Element induced wimpy testis (PIWI)-interaction RNA (piRNA). Although piRNAs typically function in complex with piwi proteins to posttranscriptionally regulate several pathways important in transposon silencing, genome rearrangement, and germ stem-cell maintenance, the most well-studied RNAi molecules are siRNAs and miRNAs that regulate gene expression at the posttranscriptional level by specific or semi-specific targeting of messenger RNA (mRNA) (Lai et al., 2013; Catalanotto et al., 2016; Han et al., 2017). Altogether, the discovery and application of RNAi technology provides a unique and adaptable tool for basic genetic and biomedical...
research and opens doors for its exploitation in the development of novel biotechnologies and therapies.

RNAi therapy uses the natural, cellular mechanisms of RNAi to bring gene regulation into clinical practice (Hayes et al., 2014; Mollaei et al., 2019; Yu et al., 2020b; Smith et al., 2022). With four novel RNAi-based therapeutics approval by the United States Food and Drug Administration (FDA), namely patisiran (FDA, 2018), givosiran (FDA, 2019), lumasiran (FDA, 2020), and inclisiran (FDA, 2021), each siRNA drug selectively acts on a target mRNA transcript to combat a disease. In addition, several siRNA agents (e.g., fitusiran, nedosiran, teprasiran, tivanisiran, and vutrisiran) have entered Phase III clinical trials with many other RNAi-based therapeutics progressing through early-stage clinical trials or preclinical development (Zhang et al., 2021a). However, delivery of RNAi therapeutics has long been the root obstacle in the way of clinical success. Once an RNAi drug is administered to the body there are several physical and pharmacokinetic barriers that limit its actions and desired efficacy (Fan and de Lannoy, 2014; Johannes and Lucchino, 2018; Seth et al., 2019; Smith et al., 2022). Chemical modifications and the development of novel delivery methods compatible with RNAi machinery help researchers overcome these barriers (Maguregui and Abe, 2020; Smith et al., 2022). Although these modifications are intended to enhance stability and improve efficacy, growing evidence suggests that chemical modifications of in vivo synthesized RNAi molecules can increase the risk of off-target effects by altering their structure, folding, biological activity, and safety away from natural RNAi agents (Morena et al., 2018; Yu et al., 2019). To address this challenge, novel technologies in development today seek to utilize intact cells to yield true
biological RNA molecules that better recapitulate the structures, stabilities, activities, and safety profiles of endogenous RNAi molecules.

In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the pharmacokinetic barriers to therapeutic RNAs, and a summary of the viable chemical modifications and delivery platforms in use. We overview the pharmacology of the four siRNA medications approved by the United States FDA, as well as five therapeutic siRNAs and several RNAi-based therapeutics currently in clinical trials. Furthermore, we discuss novel approaches to in vivo production of RNA agents, including direct expression and utilization of stable carriers, which represent a novel class of real biological RNAi molecules for research and development.

2. RNAi Molecules and Mechanisms

Genome-derived miRNAs and exogenous siRNAs are classes of ncRNA molecules of with functions in posttranslational gene regulation that make up two of the most well-studied RNAi molecules (Carthew and Sontheimer, 2009). Functional genome-derived miRNAs rang from eighteen to twenty-five nucleotides in length and are capable of targeting the mRNA transcripts of multiple genes to regulate common or several cellular pathways, while exogenous siRNA are generally introduced into the cells to control the expression of a single target gene (Huntzinger and Izaurralde, 2011; Vasudevan, 2012; Catalanotto et al., 2016; Setten et al., 2019; Smith et al., 2022). As such, these ncRNA molecules can play critical roles in modulating essentially all
cellular functions, including cell signaling, proliferation, metabolism, immunity, and senescence among others (Carthew and Sontheimer, 2009; Catalanotto et al., 2016; Piletic and Kunej, 2016).

2.1. Genome-derived miRNAs

Canonical biogenesis of genome-derived miRNA is categorized into two major phases, nuclear and cytosolic (Figure 1). Furthermore, depending on the location of the miRNA gene within the genome, miRNAs can be further classified into intergenic- and intragenic-derived miRNAs. Intergenic-derived miRNA come from regions of the genome located in noncoding regions of the DNA between genes, have unique promoter regions, and are transcribed either by RNA polymerase II or III (Ha and Kim, 2014; Valinezhad Orang et al., 2014; Liu et al., 2018). By contrast, the genes of intragenic-derived miRNA are located within exons or introns of protein-coding genes, are co-expressed with their host gene, and transcribed by RNA polymerase II (Ha and Kim, 2014; Valinezhad Orang et al., 2014). Initiating in the nuclear phase, DNA sequences encoding miRNA genes are transcribed by RNA polymerases into long hairpin transcripts called primary-miRNAs (pri-miRNAs) (Ha and Kim, 2014). A pri-miRNA is typically over one thousand nucleotides in length and consists of three major domains important to miRNA processing: a thirty-three to thirty-five nucleotide long stem, terminal loop, and two single-stranded RNA (ssRNA) segments flaking both ends (Ha and Kim, 2014). Pri-miRNA is further processed in the nucleus by the microprocessor which contains a nuclear RNase III enzyme (Drosha) and its cofactor, DiGeorge Syndrome Critical Region 8 (DGCR8) (Denli et al., 2004), to release a smaller hairpin RNA (approximately 65 nucleotides in length), termed pre-miRNA. Between the major nuclear and cytosolic phases, pre-miRNA form a complex with Exportin 5
transporter and GTP-binding nuclear protein (RAN) to exit the nucleus and release the pre-miRNA into the cytosol upon GTP hydrolysis (Okada et al., 2009).

In the cytosolic phase, pre-miRNAs are identified and further processed by RNase III endonuclease (Dicer) and the transactivating response RNA-binding protein (TRBP) (Denli et al., 2004; Okada et al., 2009; Ha and Kim, 2014) at the terminal loops of the hairpins to miRNA duplexes with two 3’ overhangs (Zhang et al., 2004). After a duplex is unwound, the guide (antisense) strand or mature miRNA is loaded into the RNA-Induced Silencing Complex (RISC) to form a miRNA-RISC complex (miRISC) while the passenger (sense) strand is degraded (Yoda et al., 2010). Determining the guide strand from the miRNA duplex is believed to be a result of Argonaute 2 endonuclease (AGO2) preference for the 3-prime terminus (3’) or 5-prime terminus (5’) and is typically variable and dependent heavily on both cell type and function (Meijer et al., 2014). AGO2 tends to preferentially select the guide strand (3’ or 5’) of the miRNA duplex with a lower stability or instead the presence of an uracil at its 5’ terminus (Khvorova et al., 2003). Following the formation of functional miRISC, the mechanism of regulation is then dependent on the interactions between the miRNA and mRNA sequences (Ha and Kim, 2014; Meijer et al., 2014).

In addition to the canonical pathways, previous studies have identified noncanonical biogenesis of miRNAs. The well-studied noncanonical pathways are categorized by the canonical processing steps they circumvent. The first major noncanonical biogenesis pathway pertains to the nuclear processing phase, independent of Drosha/DGCR8 (Figure 1). In particular, short hairpin RNA (shRNA)-bearing miRtrons derived from the genome are processed into pre-
miRNAs via posttranscriptional splicing to closely resemble Dicer/TRBP recognizable substrates for intracellular translocation and cytoplasmic processing (Westholm and Lai, 2011). After the miRtron-derived pre-miRNAs are exported into the cytosol, the second major noncanonical biogenesis pathway pertaining to the cytosolic processing phase independent of the microprocessor (Berezikov et al., 2007; Ruby et al., 2007; Westholm and Lai, 2011) (Figure 1). However, Dicer/TRBP-independent pre-miRNAs require Ago2 to cleave the 3’ strand and forming a pseudo-miRISC followed by 5’ strand trimming to mature length (Cheloufi et al., 2010; Yang et al., 2010).

Besides canonical and noncanonical biogenesis of miRNAs described above, some miRNAs are directly derived from alternative precursor RNA molecules such as small nucleolar RNAs (snoRNAs) and transfer RNAs (tRNAs) (Ender et al., 2008; Hasler et al., 2016; Patterson et al., 2017; Li et al., 2018) (Pan et al., 2013). SnoRNAs have a generalized and well-established function of controlling gene expression by modifying ribosomal RNA (rRNA) (Kufel and Grzechnik, 2019). Like canonical miRNAs, some snoRNAs are found to repress mRNAs by incorporation into the RISC complex (Ender et al., 2008; Patterson et al., 2017). MiRNAs derived from tRNA precursors constitute a unique source for miRNA maturation where suitable Dicer enzyme substrates are found within the colloquial “clover-leaf” structure of tRNAs (Hasler et al., 2016; Li et al., 2018). Precursor tRNA substrates are cleaved by Dicer into tRNA-derived RNA fragments (tRFs) with the capacity for RISC incorporation and gene regulation (Kumar et al., 2014; Hasler et al., 2016). Further, researchers have also revealed tRFs to guide Ago proteins towards target gene regulation independent of Dicer (Kuscu et al., 2018).
2.2. Exogenous siRNAs

Since their discovery following miRNA in 1998, siRNAs have become well-established, gene specific regulatory molecules that function within the RNAi pathway (Fire et al., 1998; Hamilton and Baulcombe, 1999). With several endogenous sources of siRNA identified, a major source for RNAi studies use exogenous siRNAs that are chemically synthesized and highly selectively to the mRNA transcripts of proteins previously considered to be “undruggable” by small molecule inhibitors (Setten et al., 2019; Smith et al., 2022). Exogenous siRNAs are synthesized as shRNA ranging from twenty to twenty-five base pairs with 3’ overhangs that can bypassing Dicer cleavage for direct incorporation into the RISC (siRISC) to control target gene expression when introduced to the cells (Figure 1) (Gaglione and Messere, 2010; Setten et al., 2019).

There are two well established approaches to produce siRNAs, chemical (e.g., solid-phase synthesis) and biochemical (e.g., in vitro transcription) syntheses. Solid-phase organic synthesis is a widely used method that can produce large amounts of RNAs and accommodate a wide range of chemical modifications (Amarzguioui et al., 2005). The principle is boiled down to the addition of individual ribonucleosides performed on a solid support or resin, consisting of nucleoside deprotection, coupling, oxidation, and capping. By repeating the cycle for desired number and sequence of nucleosides, the process is ended with oligonucleotide cleavage from the solid support and nucleoside deprotection (Beaucage, 2008; Francis and Resendiz, 2017). This general design uses 2'-hydroxyl protecting groups that provide ribonucleoside phosphoramidites with characteristics key to their synthetic oligomerization (Beaucage, 2008). As such, various protecting group strategies have been developed to allow for site-specific
incorporation of chemically modified groups at specific positions within the siRNA (Wilson and Keefe, 2006). In fact, the ability to synthesize siRNA with modify chemistries while retaining their regulatory function lead to the development of the enhanced stability chemistry (ESC) platform used in three out of the four FDA approved siRNA therapeutics (Foster et al., 2018; FDA, 2019; FDA, 2020; FDA, 2021).

Another way to produce siRNAs follows the principals of enzymatic reactions which commonly starts from *in vitro* transcription (IVT) (Beckert and Masquida, 2011; Yu et al., 2020a). Divergent from chemical synthesis, IVT requires a DNA template corresponding to target RNAs as well as proper RNA polymerases such as T7 phage RNA polymerase (Donze and Picard, 2002; Yu et al., 2020a). Specifically, siRNA can be produced in two general steps. Firstly, IVTs are constructed to offer two complementary ssRNAs separately, which can be annealed to offer target double-stranded RNA (dsRNAs) (Wianny and Zernicka-Goetz, 2000; Yang et al., 2002; Yu et al., 2020a). Secondly, recombinant RNases such as Dicer are employed to further process the dsRNAs into desired siRNA agents (Myers et al., 2003; Guiley et al., 2012). Of note, chemically synthesized RNA molecules can also be processed enzymatically to produce target siRNAs *in vitro* (Yang et al., 2002; Yu et al., 2020a).

Chemical modifications to siRNAs and miRNA mimics can be quite valuable to investigatory and clinical research, such as changes in phosphodiester backbone, ribose, nucleobases, or addition of non-nucleotide molecules (Setten et al., 2019; Smith et al., 2022). The theoretical goals of these optimizations are three fold. First, structural optimization may improve RNAi potency and target selectivity besides improved metabolic stability (Bramsen et al., 2009; Janas
et al., 2018). Second, optimization may decrease therapeutic immunogenicity and therefore improve overall safety (Robbins et al., 2007; Maguregui and Abe, 2020). Finally, optimization may increase tissue- or organ-targeting specificity by conjugating receptor specific ligands or by changing the physical conformation or chemical properties to increase uptake and endosomal escape into the cytosol (Lonn et al., 2016; Shum and Rossi, 2016; Chakraborty et al., 2017; Foster et al., 2018; Janas et al., 2018; Maguregui and Abe, 2020; Zhang et al., 2021a).

Depending on forms of modifications, a synthetic siRNA can have variable advantages that change properties such as biological activity, thermodynamic stability, and nuclease resistance and are categorized based on the components modified (Gaglione and Messere, 2010). For example, modifications to the 2’ region of the ribose with 2’-O-methyl, 2’-fluoro, or 2’-O-(2-methoxyethyl) can reduce immunogenicity and improve stability and resistance to degradation by nucleases (Khvorova and Watts, 2017; Maguregui and Abe, 2020). SiRNA with a partially phosphorothioated (PS) backbone may increase non-specific, gymnotal uptake (Lima et al., 2012). It was also reported that replacing the negatively charged phosphodiester backbone with a charge-neutralizing phosphotriester led to an alternative form of siRNAs termed short interfering ribonucleic neutrals that could aid in drug delivery (Meade et al., 2014).

2.3. MiRNA and siRNA functions in posttranscriptional gene regulation

Despite the differences in canonical and noncanonical biogenesis of miRNA as well as the introduction of exogenous RNAi agents, the mechanisms of actions of miRNAs and siRNAs once incorporated within the RISC are largely the same (Figure 1). However, the type of
regulation imposed on the mRNA is dependent on the RNAi agent. SiRISC typically targets and cleaves a single, specific mRNA transcript leading to mRNA cleavage and degradation while miRISC typically targets several specific mRNA transcripts leading to translational repression, mRNA cleavage and degradation, or occasionally translational activation (Ha and Kim, 2014).

Furthermore, both siRNAs and miRNAs are typically selective to specific regions of the mRNAs to regulate gene expression. In general, miRISC act through imperfect or partial complementarity to the 3’ untranslatable region (3’UTR) of its target mRNA transcripts providing a wider range of target mRNA (Ender et al., 2008; Ha and Kim, 2014; Ipsaro and Joshua-Tor, 2015; Hasler et al., 2016; Patterson et al., 2017; Kuscu et al., 2018). Instead, the typical siRISC will create a perfect complimentary match to the protein coding region or coding DNA sequence (CDS) of a single target mRNA (Lai et al., 2013). While this is true for most endogenous and synthetic siRNA, three of the FDA approved siRNA therapeutics actually follow the same mechanism of action as miRISC by binding to the 3’UTR, although they bind with perfect complementarity and designed to result in transcript cleavage (Figure 2) (Coelho et al., 2013; Khvorova, 2017; Liebow et al., 2017).

3. Therapeutic SiRNAs

Four siRNA medications (Patisiran, approved in 2018; Givosiran, 2019; Lumasiran, 2020; Inclisiran, 2021) have been approved by the United States FDA, adding to the growing list of oligoribonucleotide drugs (Yu et al., 2019; Yu et al., 2020b; Smith et al., 2022). The designs of these novel siRNA medications are founded on the basic functions and the adaptability of RNAi-
based target gene regulation (FDA, 2018; FDA, 2019; FDA, 2020; FDA, 2021) (Table 1). To gain FDA approval, each siRNA-based medication underwent its own series of rigorous clinical trials to determine both the efficacy and safety.

3.1. FDA approved siRNA medications

3.1.1. Patisiran

The development and initial FDA approval of Patisiran (brand name: Onpattro®) in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) (Table 1) ushered in a first-of-its kind RNAi therapeutic (FDA, 2018). Amyloidosis is a rare buildup of amyloid plaques that are not directly produced within the body formed through the aggregation of several different protein types including transthyretin, a protein encoded by the transthyretin (TTR) mRNA transcript primarily produced in the liver (Goldman and Schafer, 2016; Kristen et al., 2019). Amyloid formed in hATTR is molecularly characterized as an accumulation of misfolded TTR protein forming amyloid fibrils and clinically manifests as sensorimotor and autonomic neuropathy, cardiomyopathy, arrhythmia, dyspnea, shortness of breath, edema, carpal tunnel syndrome, renal impairment, vitreous opacities, glaucoma and/or pupillary disorders (Ando et al., 2006; Dungu et al., 2012; Shin and Robinson-Papp, 2012; Kristen et al., 2019).

Patisiran is to exhibit effectiveness in specifically reducing the abundance of both the wild-type and mutant, misfolded forms of TTR by RNAi regulation (FDA, 2018). Patisiran consists of two twenty-one-nucleotide long strands with eleven 2’-OMe modifications on all pyrimidines present
in the sense strand and two uridines in the antisense strand, encapsulated within a lipid
nanoparticle (LNP) (Coelho et al., 2013; FDA, 2018) (Table 1). This LNP (Figure 2) includes
cholesterol and distearoylphosphatidylcholine (DSPC) [1,2-distearoyl-sn-glycero-3-
phosphocholine] with the addition of polyethylene glycol (PEG)-lips and ionizable amino
DLin-MC3-DMA lipids to transport siRNA for circulation stability (Leung et al., 2012;
Paunovska et al., 2022). The LNP assists in hepatocyte uptake of patisiran; upon endosomal
release, the siRNAs are loaded into the RISC to specifically target and cleave TTR transcripts
(Leung et al., 2012; Kristen et al., 2019; Paunovska et al., 2022). Interestingly, the actions of
patisiran follows that of miRNAs by specifically target the 3’UTR (Figure 2) of TTR instead of
the CDS region commonly targeted by a siRNA (Kristen et al., 2019).

Prior to FDA approval, patisiran underwent a series of rigorous clinical trials. Initially, patisiran
went through two Phase I, placebo-controlled clinical trials (NCT01559077 and NCT02053454),
in particular, dose-escalation studies ranging from 0.01 to 0.5 mg/kg (Zhang et al., 2019). Phase
II placebo-controlled clinical trials were broken into two arms, the first arm (NCT01617967)
used a multiple ascending-dose study in patients afflicted by hATTR where patients receive
multiple doses in ascending concentration of 0.01, 0.05, 0.15, or 0.3 mg/kg every four weeks or
0.3 mg/kg every three weeks (Suhr et al., 2015; Taylor et al., 2018; Kristen et al., 2019). The
second arm was a long-term, placebo-controlled, and open-label extension (OLE) study
(NCT01961921) for individuals who successfully completed the initial Phase II study to further
characterize the safety and tolerability of long-term patisiran administration (Kristen et al.,
2019). Finally, in the pivotal Phase III, placebo-controlled clinical trials (APOLLO;
NCT1960348), patients received an administration of patisiran (0.3 mg/kg) once every
three weeks for 18 months (Kristen et al., 2019; Gonzalez-Duarte et al., 2020; Obici et al., 2020). Conclusion based on the completed Phase III study saw a significant improvement in hATTR clinical manifestations as well as in improvement of patient quality of life in patisiran-treated patients (Adams et al., 2018; Obici et al., 2020). In addition, the APOLLO clinical trials assessed the effects of patisiran treatment on the cardiac structure and function on hATTR patients and resulted in a reduction of cardiac wall thickness, global longitudinal strain as well as increased end-diastolic volume increased cardiac output suggesting that treatment may also reverse the effects of cardiac associated hATTR (Solomon et al., 2019).

Evidence from clinical trials suggests patisiran to be well tolerated with a consistent and agreeable safety profile in afflicted patients, minimal dispersant of intravenous (iv) administered patisiran to off-target organs, and minimal drug accumulation following additional doses suggesting patisiran siRNA to be cleared via nuclease activity (Coelho et al., 2013; Suhr et al., 2015; Adams et al., 2018). To further evaluate the safety and efficacy of long-term patisiran administration, patients who completed both the Phase II OLE and Phase III were enrolled into an ongoing global OLE study (NCT02510261) to (Adams et al., 2021). Patisiran, is seeing a second ongoing Phase III clinical trial (NCT03997383) for hATTR in patients that suffer with a cardiomyopathy comorbidity. Today, patisiran is commercially available with a recommended dose of 0.3 mg/kg every 3 weeks administered through iv infusion over 80 minutes (FDA, 2018).

Overall, the impact of patisiran provided three major contributions to the areas of RNAi therapy. First, patisiran served as the first RNAi-based therapeutic approved by the FDA that is designed to use endogenous RNAi machinery to control the outcome of disease-causing proteins. This
work carved a path of success that other RNAi therapeutics would soon follow. Second, the method of action of patisiran closely mirrors that of endogenous miRNA by targeting the 3’UTR of TTR and supports the potential of future successful miRNA therapeutic development to combat disease. Finally, the development of patisiran is a foundation upon which ongoing research has improved and innovated RNAi technology to be widely applicable and appropriately manipulated to target and remedy molecular disease components.

3.1.2. Givosiran

Givosiran (brand name: Givlaari®) was the second siRNA drug to receive its first FDA approval in 2019 for the treatment of acute hepatic porphyria (AHP) (FDA, 2019) (Table 1). AHP is a rare genetic disorder derived from the liver and caused by a dysfunction within the heme synthesis pathway that causes an upregulation of aminolevulinate synthase 1 (ALAS1) and an increase ALAS1 protein expression (Bissell et al., 2017; Anderson, 2019; Scott, 2020; Kothadia et al., 2022; Sardh and Harper, 2022). Dysregulated ALAS1 expression is known to increase downstream production of neurotoxic metabolites, aminolevulinic acid and porphobilinogen, causing AHP (Anderson, 2019; Kothadia et al., 2022). AHP is clinical characterized by severe and debilitating abdominal pain, hypertension, tachycardia, vomiting, seizures, paralysis, and often associated with neuropathy, chronic kidney disease, and liver disease (Besur et al., 2014; Pallet et al., 2018; Anderson, 2019; Sardh and Harper, 2022).

Givosiran is designed as an effective treatment against AHP by reducing the abundance of ALAS1 by RNAi regulation (FDA, 2019). Givosiran consists of a double-stranded, chemically
synthesized and fully modified twenty-three-nucleotide long antisense strand and twenty-one-nucleotide long sense strand with tri-N-acetylgalactosamine (GalNAc)-conjugation to enhance liver selective delivery (FDA, 2019; Debacker et al., 2020; Sardh and Harper, 2022). Further, givosiran also uses sixteen 2'-F substitutions with the remaining as 2’-OMe substitutions as well as six terminal PS chemical modifications (FDA, 2019) (Table 1). Unlike patisiran, givosiran is administered via subcutaneous (sc) injection to target and inhibit the translation of ALAS1 mRNA (FDA, 2019). The tri-GalNAc delivery platform exploits the biological interaction between the GalNAc molecules found on damaged glycoproteins and the asialoglycoprotein receptor 1 (ASGR1) found at high levels on hepatocytes to target givosiran to the liver (Debacker et al., 2020; Sardh and Harper, 2022) (Figure 2). The givosiran siRNA payload is designed to target a specific sequence on the CDS (Figure 2) of ALAS1, decrease ALAS1 protein abundance and the production of the neurotoxic metabolites, and treat AHP (Agarwal et al., 2020; Sardh and Harper, 2022).

Givosiran also underwent a series of rigorous clinical trials prior to regulatory approval. In Phase I, placebo-controlled clinical trials (NCT02452372) were separated into three dosing regiments based on patient AHP frequency: A (infrequent AHP; single-ascending dose sc injections of 0.035, 0.10, 0.35, 1.0, or 2.5 mg/kg), B (moderate frequency; once monthly dose sc injections of 0.35 or 1.0 mg/kg), and C (frequent; once monthly or quarterly dose sc injections of 2.5 or 5.0 mg/kg) (Sardh et al., 2019; Sardh and Harper, 2022). Patients who successfully completed Phase IC were enrolled in Phase I/II, placebo-controlled OLE with the goal to rapidly and sustainably lower hepatic ALAS1 mRNA and urinary neurotoxic metabolite levels as well as reduce the rate of AHP attacks in patients with ongoing attacks through extended givosiran treatment (Bissell et
al., 2019; Sardh and Harper, 2022). In the pivotal Phase III, placebo-controlled clinical trials (ENVISION; NCT03338816) were performed on symptomatic patients who received once monthly sc injections of givosiran (2.5 mg/kg) for six months (Balwani et al., 2020; Sardh and Harper, 2022).

Clinical evidence shows that givosiran-treated patients saw a significant reduction in AHP attacks (74%) and sustained reduction in urinary aminolevulinic acid and porphobilinogen neurotoxic metabolite levels as well as decreased daily pain and an improved quality of life patients (Balwani et al., 2020; Sardh and Harper, 2022). However, success was accompanied by an increase in adverse hepatic and renal events seen in few givosiran-treated patients (Balwani et al., 2020; Sardh and Harper, 2022). In a later study designed to define further assess the safety and efficacy of givosiran showed evidence that regular givosiran treatments did indeed reduce the rate of AHP attacks, benefited patients with recurrent AHP attacks, improved quality of life, and supported the safety of givosiran (Sardh and Harper, 2022; Ventura et al., 2022). Today, givosiran is commercially available with a recommended dose of 2.5 mg/kg once a month via sc injection (FDA, 2019).

The success of givosiran provides three major impacts to the fields of molecular biology and therapeutics. First, as a chemically modified siRNA therapeutic givosiran serves as evidence that chemical alterations to RNAi technology can be implemented and manipulated to optimize molecular interactions to target and remedy disease. Second, the successful delivery of givosiran demonstrates a major advancement in RNAi therapeutics with a drug delivery platform capable of selective delivery to hepatocytes by the GalNAc delivery platform used in future siRNA
therapeutics. Finally, givosiran further supports the use of RNAi-based therapeutics to combat diseases that can be largely at the mercy of ineffective treatment options or deemed undruggable targets by small molecules.

### 3.1.3. Lumasiran

Lumasiran (brand name: Oxlumo®), was the third siRNA medication to receive its first FDA approval in 2020 for the treatment of primary hyperoxaluria type 1 (PH1) (FDA, 2020) (Table 1). PH1 is a rare, autosomal recessive disorder originating in the liver that is caused by a decrease in peroxisomal enzyme alanine-glycolate aminotransferase (AGT), an enzyme responsible for glyoxylate metabolism inhibition, and results in the deposition of calcium oxalate crystals in the kidneys and urinary tract (Cochat and Rumsby, 2013; Garrelfs et al., 2021). PH1 is clinically characterized by nephrolithiasis and nephrocalcinosis of the kidney leading to kidney disease or failure and systemic oxalosis, the systemic deposition of calcium oxalate crystals (Cochat and Rumsby, 2013).

Lumasiran is designed as an effective treatment for PH1 by reducing the abundance of oxalate deposition by RNAi regulation alternative to dialysis, kidney transplant, or vitamin B6 supplementation (Cochat and Rumsby, 2013; FDA, 2020). Lumasiran consists of a fully modified siRNA with a twenty-three-nucleotide long antisense strand, twenty-one long sense strand with tri-GalNAc-conjugation, and ten 2′-F, thirty-four 2′-OMe, and six terminal PS chemical modifications (Table 1) (FDA, 2020). Lumasiran is also administered sc to patients with specific delivery to the liver and targets the 3′UTR (Figure 2) of the hydroxyacid oxidase 1
(HAO1) mRNA transcript that encodes glycolate oxidase (GO); an upstream enzyme in the oxalate overproduction pathway (Liebow et al., 2017; Debacker et al., 2020; FDA, 2020).

Like that of its predecessors, lumasiran underwent a series of rigorous trials to attain FDA approval. Initial Phase I/II, placebo-based clinical trials (NCT02706886) consisted of three different dosing regimens to determine appropriate dosing of either three monthly doses of 1 mg/kg, three monthly doses of 3 mg/kg, or two single doses of 3 mg/kg every three months, followed by an OLE (Frishberg et al., 2021). The pivotal Phase III, placebo-controlled clinical trials were broken into three unique arms termed ILLUMINATE-A (NCT03681184), ILLUMINATE-B (NCT03905694), and ILLUMINATE-C (NCT03681184). ILLUMINATE-A studied the effects of lumasiran in children and adults over the age of six and received three months of lumasiran followed by quarterly maintenance doses of 3 mg/kg that extended into a 54-month dose evaluation OLE period to assess safety and efficacy (Garrelfs et al., 2021). In ILLUMINATE-B, patients under the age of six received similar lumasiran treatments (Sas et al., 2021). ILLUMINATE-C (NCT03681184) is currently ongoing and designed to evaluate the efficacy and safety of lumasiran for patients with advanced PH1 and estimated completion date of July 2025 (Scott and Keam, 2021). Following the success of ILLUMINATE-A and ILLUMINATE-B, patients who successfully completed these studies were enrolled into an ongoing OLE period to evaluate the long-term efficacy and safety of lumasiran in adults and children with PH1 (NCT03350451) (Scott and Keam, 2021).

Based on evidence from clinical trials, lumasiran was well tolerated in both children and adult cohorts, demonstrated an acceptable safety, and was shown to beneficially reduce oxalate levels
independent of age, sex, race, abnormal kidney function, vitamin B6 use, or history of symptomatic kidney stone events (Garrelfs et al., 2021; Sas et al., 2021). Today, lumasiran is commercially available with a recommended sc administration dose dependent on body weight (FDA, 2020). For patients less than 10 kg the recommended administration has a loading dose of lumasiran is 6 mg/kg once monthly for 3 doses followed by a once monthly maintenance dose of 3 mg/kg. For patients between 10 kg and 20 kg, the recommended administration has a loading dose of lumasiran is 6 mg/kg once monthly for 3 doses followed by a once quarterly maintenance dose of 6 mg/kg. For patients 20 kg and above, the recommended administration has a loading dose of lumasiran is 3 mg/kg once monthly for 3 doses followed by a once quarterly maintenance dose of 3 mg/kg.

The success and approval of lumasiran provides two major impacts to the fields of molecular medicine. First, lumasiran serves as additional RNAi-based therapeutics that further supports the use of RNAi as a means to combat disease and the method of action of lumasiran once again closely mirrors that of endogenous miRNA and therefore further support the development of miRNA drugs. Second, successful administration and action of lumasiran further serves as evidence that RNAi technology can be implemented and manipulated to optimize molecular interactions to target and remedy disease.

3.1.4. Inclisiran

The most recent siRNA therapeutics approved by the FDA in 2021, inclisiran (brand name: Leqvio®), is a first-in-class siRNA medication designed to treat heterozygous familial
hypercholesterolemia (HeFH) and clinical atherosclerotic cardiovascular disease (ASCVD) in combination with maximally tolerated statin therapy (FDA, 2021) (Table 1). Both HeFH and ASCVD are similarly characterized by an increase in low-density lipoprotein cholesterol (LDL-C) in circulation (McGowan et al., 2019; Bardolia et al., 2021). HeFH is a familial, autosomal codominant genetic disorder caused by a protein mutation within lipoprotein metabolism that leads to a high accumulation of LDL-C in the blood plasma. Mutations in the LDL receptor (LDL-R) are identified in 85%-90% of cases and a gain-of-function (GoF) mutation in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene identified in roughly 1% of confirmed HeFH cases (Abifadel et al., 2003; McGowan et al., 2019). PCSK9 is a low abundant circulating protein with a critical function in the low-density lipoprotein cholesterol metabolic pathway were a GoF mutation within the PCSK9 gene further enhances its function to decrease natural LDL recycling untimely resulting in hypercholesterolemia (Abifadel et al., 2003). Chronic elevated LCL-C levels seen in hypercholesterolemia often results in a comorbidity with ASCVD, a thickening and loss of elasticity in the arterial wall (McGowan et al., 2019; Bardolia et al., 2021). Prior to inclisiran, the PCSK9 inhibition was facilitated through the use of two monoclonal antibodies, evolocumab and alirocumab, that function by blocking the LDL-R, however their safety and efficacy continue to be under investigation in based on data reported by Clinicaltrials.gov (van Bruggen et al., 2020; Santulli et al., 2021).

Unique among siRNA therapeutics, inclisiran is designed as a supplemental, non-statin therapeutic to improve the effects of current treatments for cholesterol management by reducing the abondance of PCSK9 by RNAi regulation (Bardolia et al., 2021; FDA, 2021; Zhang et al., 2021a). Inclisiran consists of a fully modified siRNA with a twenty-three-nucleotide long
antisense strand, twenty-one-nucleotide long sense strand with tri-GalNAc-conjugation, and one 2′-MOE, eleven 2′-F, thirty-two 2′-OMe, and six terminal PS chemical modifications designed to target PCSK9 mRNA (FDA, 2021) (Table 1). Inclisiran is administered sc to patients to inhibit PCSK9 protein synthesis, decrease the influence if PCSK9 on natural LDL recycling by binding to the 3’UTR of PCSK9 mRNA and interfering with its translation (Nair et al., 2014; Khvorova, 2017; FDA, 2021; Lamb, 2021) (Figure 2).

As all approved siRNA therapeutics before it, inclisiran underwent a series of rigorous trials to prior to FDA approval. Initial Phase I, placebo-controlled clinical trials (NCT02314442) were broken into two arms to study the effects of inclisiran treatment. Arm one was a single-ascending dose study dosed at either 25, 100, 300, 500, or 800 mg and arm two was a multiple-ascending dose study with dose regimens of either four weekly doses at 125 mg, two doses every other week at 250 mg, or two monthly doses of either 300 or 500 mg done with or without combination statin therapy (Fitzgerald et al., 2017). Phase II, placebo-controlled clinical trials (NCT02597127) in patients with elevated LDL-C serum levels and high cardiovascular disease risk had two multiple-ascending-dose trials, receiving either a single dose of either 200, 300, or 500 mg or patients received two doses at days 1 and 90 of either 100, 200, or 300 mg (Ray et al., 2017). The pivotal Phase III, placebo-controlled clinical trials were broken into three unique arms termed ORION-9 (NCT03397121), ORION-10 (NCT03399370), and ORION-11 (NCT03400800). ORION-9 was performed on adults with heterozygous familial hypercholesterolemia receiving 300 mg administered on days 1, 90, 270, and 450 (Raal et al., 2020). ORION-10 and ORION-11 were performed on patients on statin therapy with ASCVD or
ASCVD and equivalent ASCVD risk, respectively, receiving 284 mg at day one and day ninety followed by a dose every six months thereafter for 540 days (Ray et al., 2020).

Clinical results indicate that inclisiran-treated patients saw a reduction of approximately 50% in LDL cholesterol levels of patients treated every six months (Raal et al., 2020; Ray et al., 2020). As a newly approved therapeutic, inclisiran is currently under several Phase III studies to assess the efficacy, safety, and tolerability of long-term dosing including ORION-8 (NCT03814187), ORION-13 (NCT04659863) and ORION-16 (NCT04652726) (Brandts and Ray, 2021; Reijman et al., 2022). With a recommended initial dose of 284 mg followed by a supplemental dose at three months and maintenance doses every six months administered via sc injection, inclisiran is commercially available and prescribed for combination therapy with the maximally tolerated statins (FDA, 2021).

The success following FDA approval of inclisiran in late December 2021 has three major impacts in the fields of molecular biology and therapeutics. First, the approval of inclisiran is further validation that canonical RNAi machinery is adaptable and that modification to RNAi technology can optimize molecular interactions to specifically target and remedy disease. Second, inclisiran is the third siRNA therapeutic to closely mirrors the function of endogenous miRNA and supports the use of miRNA drug development to combat disease. Finally, with the high incidence of hypercholesterolemia, inclisiran offers a unique, first-in-class, non-statin treatment to help combat hypercholesterolemia; where a 1.0 mmol/L reduction in LDL is suggested to reduce adverse cardiovascular events by roughly 21% (Santulli et al., 2021).
Continued studies into inclisiran explore the pharmacokinetics and safety as well as investigat emerging pharmacodynamic roles for inclisiran on biological function. In a 2022 study focused on the pharmacokinetics and pharmacodynamics of inclisiran in hepatic impaired patients, researchers found that patients with impaired hepatic function had approximately a two-fold increase in systematic exposure to inclisiran with little change in LDL-C compared to patients with no or mild hepatic impairment (Kallend et al., 2022). This suggested that hepatic impairment had little effect on treatment efficacy and showed no issues in the safety or tolerability of inclisiran which further suggested no need for dose adjustment for patients with mild or moderate hepatic impairment (Kallend et al., 2022). An additional study published recently looks into the effects of inclisiran on the formation of oxidized-LDL-induced (ox-LDL), macrophage-derived foam cells (Wang et al., 2022). In this study, the authors found inclisiran to reduce lipid accumulation and inhibited macrophage-derived foam cell formation through the activation of the PPARγ pathway (Wang et al., 2022). Since activation of the PPARγ pathway is important in fatty acid uptake and lipogenesis the results of this study suggest a possible off-target effect of inclisiran by increasing the expression of increased both the gene and protein expression of PPARγ (Christofides et al., 2021; Wang et al., 2022). Investigations into the pharmacodynamic roles of therapeutics on biological function are critical not only for understanding how medications interact with the body but also to better understand what pathways or unknown interactions are inadvertently activated that may contribute to the success or potential adverse effects of a therapeutic.

3.2. Therapeutic siRNAs in clinical trials
In addition to the four FDA approved siRNA therapeutics, several other novel siRNA have entered clinical trials with several in preclinical development (Table 2). Of these, five have reached the pivotal Phase III clinical trials, namely fitusiran (Machin and Ragni, 2018), nedosiran (Kletzmayr et al., 2020), teprasiran (Gallagher et al., 2017), tivanisiran (Moreno-Montanes et al., 2018), and vutrisiran (Habtemariam et al., 2021).

3.2.1. Fitusiran

Fitusiran (ALN-AT3SC) is a therapeutic siRNA designed for the treatment of both Hemophilia A and B, and fitusiran is currently undergoing Phase II and Phase III clinical trials (Machin and Ragni, 2018) (Table 2). Hemophilia A and B are X-linked bleeding disorders that are the result of mutations within the genes encoding coagulation factor VIII and IX, respectively, and interfere with normal blood clotting mechanisms of the body (Castaman and Matino, 2019). Fitusiran consists of a fully modified double-stranded siRNA of twenty-one- and twenty-three-nucleotides long with a tri-GalNAc-conjugate and contains twenty-one 2′-F substitutions, twenty-three 2′-OMe substitutions, and six PS modifications at the strand ends (Berk et al., 2021). Fitusiran functions by inhibiting the production of the antithrombin proteins to increase the generation of pro-coagulation enzyme, thrombin, and improve the blood clotting mechanism (Sehgal et al., 2015; Machin and Ragni, 2018).

3.2.2. Nedosiran
Nedosiran (DCR-PHXC) is another therapeutic siRNA currently in Phase III clinical trials that is designed for the treatment of primary hyperoxaluria (Kletzmayr et al., 2020) (Table 2). Nedosiran consists of a nearly fully modified siRNA duplex that forms a tetraloop configuration through interactions between its twenty-two-nucleotide long antisense strand and thirty-six-nucleotide long sense strand with tri-GalNAc conjugation as well as nineteen 2′-F substitution, thirty-five 2′-OMe substitution, and six PS modifications (Lai et al., 2018; Kletzmayr et al., 2020). Nedosiran is an up-and-coming competitor of lumasiran that is being clinically assessed for the treatment of both PH1 and primary hyperoxaluria type 2 (PH2) subtypes of primary hyperoxaluria. However, instead of targeting the upstream GO protein mRNA, nedosiran is designed to target the mRNA of the hepatic enzyme lactate dehydrogenase (LDH), an enzyme that controls the final step in glyoxylate metabolism to oxalate (Cochat and Rumsby, 2013; Kletzmayr et al., 2020).

3.2.3. Teprasiran

Teprasiran (QPI-1002) is a therapeutic siRNA currently in Phase III clinical trials that is designed to treat acute kidney injury (AKI), specifically after kidney transplant or cardiovascular surgery (Davidson and McCray, 2011; Gallagher et al., 2017) (Table 2). AKI is not inherently classified as a disease, but instead is classified as a clinical syndrome that afflicts many hospitalized patients and is defined as an abrupt decrease in kidney function because of structural damage or impairment (Makris and Spanou, 2016). Teprasiran is unique among current siRNAs in that it only consists of 2′-OMe modifications. Specifically, half of ribonucleosides within the nineteen-nucleotide long siRNA duplex are comprised of 2′-OMe substitutions, and teprasiran is
delivered as naked siRNA without other delivery system (Gallagher et al., 2017). Teprasiran functions by targeting the mRNA of the well-known tumor suppressor protein, p53, which is involved in apoptotic induction during physiological stress (Molitoris et al., 2009; Thompson et al., 2012; Gallagher et al., 2017).

3.2.4. Tivanisiran

Tivanisiran (SYL-1001) is a therapeutic siRNA designed for the treatment of ocular pain and dry eye disease (DED), and it is currently in Phase III clinical trials (Moreno-Montanes et al., 2018) (Table 2). DED is a multifactorial disease of the eye that results in several ocular abnormalities including pain, discomfort, dryness, itching, burning, and photophobia due to a disruption in the healthy tear film, ocular inflammation, or neurosensory abnormalities (Shimazaki, 2018). Tivanisiran stands alone as the only completely unmodified therapeutic siRNA composed of a nineteen-nucleotide long duplex in Phase III that is also delivered naked and without a delivery platform (Moreno-Montanes et al., 2018). Tivanisiran functions by targeting the mRNA of transient receptor potential cation channel subfamily V member 1 (TRPV1) that plays an important role in several pathways including pain signal transduction, fibrogenesis modulation, the stress response, and the innate inflammatory response (Moreno-Montanes et al., 2018).

3.2.5. Vutrisiran

Vutrisiran (ALN-TTRSC02) is a therapeutic siRNA in Phase III clinical trials that is also designed for the treatment of hATTR (Habtemariam et al., 2021) (Table 2). Vutrisiran is an up-
and-coming competitor of patisiran since both are designed to treat hATTR. Vutrisiran consists of two fully modified strands of twenty-one- and twenty-three-nucleotides long with the latest version of the tri-GalNAc conjugate delivery platform, and it also contains thirty-five 2′-OMe, nine 2′-F, and contains six PS modifications at the strand ends (Foster et al., 2018; Weng et al., 2019). With improved delivery to the liver by tri-GalNAc conjugation, vutrisiran is believed to be a more potent than patisiran yet functions similarly in the hepatocyte by targeting a conserved sequence on all TTR variants with similar actions as patisiran to treat hATTR (Foster et al., 2018; Weng et al., 2019; Habtemariam et al., 2021).

4. MicroRNA-Based Therapies under Development

4.1. Strategies of miRNA-based therapies

Alongside the extensive list of siRNAs in clinical trials, several miRNA detection technologies are FDA approved and available today to determine miRNA profiles as potential biomarkers for clinical diagnostic or prognostic purposes (Bonneau et al., 2019; Hanna et al., 2019; Smith et al., 2022). In terms of miRNA-based interventions, there are two major approaches (Bader et al., 2010; Mollaei et al., 2019; Yu et al., 2020b; Yu and Tu, 2022). One strategy, namely miRNA antagonism (anti-miR), is to inhibit or repress the expression or function of a target miRNA; and the other approach, namely miRNA replacement therapy, is to restore the expression or function of target miRNA.
Anti-miR therapy relies on sequence complementarity between the single stranded antagonir (or ASO) and target miRNA (Lima et al., 2018). In particular, antagonirs inhibit miRNA function by complimentary hybridization and/or steric hindrance of miRNA with its target mRNA or for DNA/RNA hybridization degradation by RNase H (Lennox and Behlke, 2011; Lennox et al., 2013; Mie et al., 2018). There is also growing interest in developing small molecule compounds to interfere with miRNA biogenesis or function (Velagapudi et al., 2014; Costales et al., 2017; Meyer et al., 2020; Yu et al., 2020b). Therapeutic antagonirs are typically deployed to target disease causing and overabundant miRNAs in the diseased cells, such as oncogenic miRNAs overexpressed in carcinoma cells (Stenvang et al., 2012; Mollaei et al., 2019). While miRNA replacement therapy restores miRNAs downregulated or completely lost in the diseased cells which actually function to suppress the disease, such as tumor suppressor miRNAs (Mollaei et al., 2019). Chemo-engineered miRNA mimics or viral or nonviral vectors expressing systems are typically deployed with the goal of reintroducing target miRNAs to combat disease (Yu et al., 2016; Mollaei et al., 2019; Yu et al., 2020b).

While anti-miR therapy is the prominent miRNA-based intervention currently under clinical trials, the application of miRNA replacement therapy is exemplified in previous study focused on miR-29 mimicry to block pulmonary fibrosis (Montgomery et al., 2014). MiR-29 was selected for this study based on its ability to regulate extracellular matrix proteins important in tissue fibrosis and is downregulated in fibrotic diseases (He et al., 2013; Montgomery et al., 2014). In this study, after confirming its functionality in vitro, the chemically modified, synthetic RNA duplex of miR-29 was injected iv into a mouse model of pulmonary fibrosis resulting in a
sustained increase miR-29 levels and restored endogenous miR-29 function by decreasing collagen expression and treating the disease (Montgomery et al., 2014).

One major area of study is miRNA-based anticancer treatments to combat various types of cancer (To et al., 2020; Smith et al., 2022). This is because some miRNAs, such as let-7 and miR-34, are master regulators of gene expression with the capability to modulate several critical, homeostatic cellular pathways and functions that are often found dysregulated in cancer (Catalanotto et al., 2016; Piletic and Kunej, 2016; To et al., 2020). Specific miRNAs have emerging roles in particular cancer types including human papillomavirus (HPV)-related cancers (Casarotto et al., 2020), colorectal cancers (To et al., 2018), lung cancers (Xue et al., 2017), and acute myeloid leukemias (Lovat et al., 2020) among others. As more and more oncogenic miRNAs are being examined, there has been a large influx of strategies aimed at miRNA inhibition such as: miRNA-masks, miRNA-sponges, and miRNA-zippers among others (To et al., 2020). MiRNA-masks are ASOs designed to bind the 3’UTR of target mRNA and shield or protect the mRNA from endogenous miRNA regulation in an inhibitory manner (Wang, 2011; Nguyen and Chang, 2017). MiRNA-sponges are often circular RNA (circRNA) molecules that function as a decoy to sequester or “sponge” multiple miRNAs from their target mRNA transcripts and can more easily evade nuclease degradation compared to linearized ASOs (Ebert et al., 2007; Wang, 2011). MiRNA-zippers are designed to connect miRNA molecules end-to-end forming a highly specific, highly stable DNA–RNA duplex to inhibit miRNAs from performing their functions (Meng and Lu, 2017).
Further, miRNA-based therapies are also used in combination with other well-established therapies towards optimal outcomes. In fact, combination therapy can come in many flavors and includes either miRNA antagonism in combination miRNA replacement therapy or a miRNA-based therapy in combination with existing or new treatment for a given disease. Combination therapies are most prevalent in anticancer therapy to play supportive roles in oncogenic miRNA inhibition or tumor-suppressive miRNA reintroduction. Some common forms of miRNA-based combination therapy include chemotherapy (To, 2013; Zhang and Wang, 2017), immunotherapy (Hand et al., 2010; Ji et al., 2016; Cortez et al., 2019), radiotherapy (Overgaard, 2007; Babar et al., 2011; Moertl et al., 2016; El Beawy et al., 2019), and photodynamic therapy (Kessel and Oleinick, 2018) (El-Daly et al., 2017). Of interest, one form of combination therapy uses multiple tumor-suppressor miRNA reintroduction or anti-miR miRNA inhibition to synergize and bolster the antitumor effects of treatment (Jung et al., 2015; Orellana et al., 2019). In a 2016 article, the expression of miR-621 was demonstrated to be a predictive marker for chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) treatment of breast cancer patients where elevated levels of miR-621 predicted a better response to PTX/CBP treatment (Xue et al., 2016). Researchers further established this correlation in a combination therapy study demonstrating that increased ectopic expression of miR-621 increased chemosensitivity to PTX/CBP in vitro and in vivo (Xue et al., 2016). This study demonstrates the promise of miRNA therapeutics and supports a potential role in combination therapy.

4.2. MiRNA-based therapies in clinical trials
Several miRNAs have been and continue to be tested for remedies of several disease types (Table 3), including anticancer treatment. For example, MRX34, a mimic of miR-34a, was tested as an anticancer therapeutic in two Phase II clinical trials (NCT01829971; NCT02862145) for primary liver cancer (PLC), small cell lung cancer (SCLC), lymphoma, melanoma, multiple myeloma (MM), renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). MiR-34a is a key regulator of tumor suppression controlling the expression of several targets involved in cell cycle (e.g., c-MYC, E2F, CDK4 and CDK6) and apoptosis (e.g., BCL2 and SIRT1), and tumor-associated processes such as invasion (e.g., c-MET) (Hermeking, 2010; Misso et al., 2014). MiR-34a has also shown antagonistic characteristics to cancer cell viability, stemness, metastasis and resistance to chemotherapy (Misso et al., 2014). Decreased expression of miR-34a is often associated with several types of cancer, including MM (Dimopoulos et al., 2013) and melanoma (Lodygin et al., 2008; Misso et al., 2014). The molecular structure of MRX34 consists of a twenty-three-nucleotide long, double-stranded miRNA resembling the endogenous miR-34a duplex that is encapsulated in LNP for iv administered delivery to tumors located in the liver, bone marrow, spleen, lung, and a variety of other tissues (Beg et al., 2017). Once delivered, MRX34 would interfere with target gene translation by binding to its complementary sequence in the 3'UTR of mRNAs. Although both Phase II trials were terminated due to immune related serious adverse events, MRX34 demonstrated a successful regulation of relevant target genes that provided the necessary proof-of-concept for the efficacy of miRNA-based anticancer therapy (Hong et al., 2020).

Alongside a promising future in miRNA-based anti-cancer therapy, miRNA also show potential in the treatment of cardiovascular disease. In particular, several miRNA are under investigation
for their roles in cardiomyocyte necrosis, apoptosis, and autophagy as well as cardiac fibroblast proliferation, inflammation, and angiogenesis (Kansakar et al., 2022; Varzideh et al., 2022). One miRNA-based cardiovascular therapeutic, termed CDR132L, is currently starting Phase II clinical trials for the treatment of myocardial infarctions and acute heart failure of the left sided and functions as an antagonomir of miR-132; a miRNA important in maladaptive cardiac remodeling, transformation, and hypertrophy (NCT05350969) (Table 3). A second miRNA-based cardiovascular therapeutic, MRG-110, is an antagonomir of miR-92a, that has currently completed phase I clinical trials and is intended to promote angiogenesis by inhibiting the regulatory function of miR-92a (NCT03603431) (Table 3). Together these miRNA demonstrate the critical importance of miRNA regulation to cardiovascular health and further supports the potential for miRNA as a therapeutic strategy.

Miraviren (SPC3649), an antagonomir of miR-122 (Table 3), is an example of miRNA antagonism therapy which was evaluated in Phase II clinical trials for the treatment of hepatitis C (NCT01727934; NCT01872936; NCT01200420). MiR-122 plays a central role in several aspects of liver function and is shown to stimulate hepatitis C virus (HCV) progression by binding the 5’UTR of the HCV genome (Hu et al., 2012). As an anti-miR, miraviren has sequence complementarity to endogenous mature miR-122 and is composed of several locked nucleic acid (LNAs) ribonucleotides along a DNA PS sequence (Gebert et al., 2014). In its Phase 2a clinical trial (NCT01200420), miraviren-treated patients saw prolonged dose-dependent in HCV RNA levels following sc injection (Janssen et al., 2013). This early success of antagonomirs demonstrated the functionality of anti-miR therapy as the world’s first miRNA-targeted drug and provided a revolutionary drug to treat HCV (Lindow and Kauppinen, 2012).
Following the footsteps of the CDR132L, MRG-110, and miraviren clinical trials, most current miRNA-based therapies in the clinic investigations are designed as anti-miR therapy discussed previously while restoring miRNAs that are lost or downregulated in diseased cells represents a less tapped means meriting greater attention. As highly potent regulators of gene expression, miRNAs make widely applicable therapeutic candidates since their biological function is to target several mRNA transcripts to potentially alter several cellular pathways (Catalanotto et al., 2016). This proves an opportunity for one therapeutic to target and alter the effects of several critical pathways found dysregulated in disease. However, it is this same natural property that limits the specificity of an miRNA as treatment to one disease causing pathway and increases the risk of off-target effects, therefore, complicating its pharmacology and candidacy as a therapeutics, such as seen with MRX34 (Hong et al., 2020; Segal and Slack, 2020; Zhang et al., 2021b). This characteristic of miRNA has recently been termed “too many targets for miRNA effect” (TMTME), or in other words the complication that one miRNA therapeutic candidate does indeed have the ability to target many mRNA transcripts and therefore adds another major obstacle unique to miRNA in the path of success in clinical trials (Montgomery et al., 2014; Zhang et al., 2021b). While the probability for a single miRNA therapeutic to achieve its targeted effect is likely, the potency of miRNA towards effecting additional targets that are on-target for the miRNA itself but are off-target for the therapeutics, and can have unprecedented or unpreventable consequences depending on its pharmacological properties (Segal and Slack, 2020; Zhang et al., 2021b). Therefore, much work remains to be done to address toxic off-target effects and enhancing specific or targeted delivery platforms to develop and improve miRNA therapeutics with increased odds of clinical success.
However, in a recently published article researchers sought to tackle the challenge of TMTME by integrating data from multi-omic studies with a developed algorithm to identify candidate miRNAs with the potential for miRNA-based therapy for Ewing Sarcoma with minimal effect on essential housekeeping genes (Weaver et al., 2021). Their approach estimates the “network potential” of a tumor based on collective transcriptomic and protein-protein interactions within the tumor and ranks relevant target mRNAs and identifies prime miRNAs or miRNA combinations to repress those targets (Weaver et al., 2021). This work is a real time example of current research being done to improve the odds of clinical success and personalize miRNA therapeutics for the greatest effect on cancer progression.

5. Approaches and Challenges in Delivering RNAi Therapeutics

One obstacle faced by all forms of medications, including RNAi therapeutics discussed in this review, is to ensure an effective and safe level of therapeutic agents to overcome systemic barriers and access the target in specific cells, tissues or organs (Dowdy, 2017; Paunovska et al., 2022; Smith et al., 2022). Without a viable strategy for protection or tissue-selective delivery, therapeutic RNAs face metabolism by circulating and liver enzymes, such as hydrolases and RNases, and rapid clearance from the body by the kidneys after administration, which both would limit target tissue distribution or delivery. Nevertheless, hepatic and nonhepatic metabolism as well as renal and biliary clearance are critical components for the body to eliminate xenobiotic agents, including medications and toxins.
Furthermore, since RNAi agents typically interact with intercellular components and on intracellular targets, they need to cross the cellular membrane which poses another major challenge to delivery due to the large molecular structure and strong, negatively charged nature of RNA and oligonucleotide molecules. Therefore, tailoring “delivery” strategies toward favorable pharmacokinetic properties, including biodistribution of the right levels of therapeutic RNAs to the target tissues and into the target cells to selectively access molecular targets, is critical to achieve the desired efficacy and safety among patients. The introduction of chemical modifications (Micklefield, 2001; Setten et al., 2019; Smith et al., 2022), as discussed previously, is a proven approach that provides an advantage by increasing RNA metabolic stability, ensuring efficacious pharmacological actions, and avoiding non-selective or adverse effects. As such, delivery strategies using chemically modified siRNA such as patisiran, givosiran, lumasiran, and inclisiran discussed previously have attained FDA approval. However, chemical modification introduce a disadvantage by compromising the initial chemical and physical characteristics and activities of naturally synthesized, modified, and folded RNA (Morena et al., 2018; Yu et al., 2019; Yu et al., 2020a; Yu et al., 2020b). In fact, recent studies on inclisiran discussed previously suggest possible off-target effects of the therapeutic away from its FDA designated biological activity providing the possibility for off-target effects even in RNAi designed with chemically modifications for target specificity (Christofides et al., 2021; FDA, 2021; Wang et al., 2022).

Delivery platforms can also be tailored to the unique characteristics of a diseased cell. For example, some delivery tactics connect RNAi agents to tissue- or receptor-specific ligands, such as an antibody fragment, an entire antibody, or the FDA approved tri-GalNAc conjugate to target
specific receptors or membrane proteins for internalization (FDA, 2019; Seth et al., 2019; FDA, 2020; Maguregui and Abe, 2020; FDA, 2021; Paunovska et al., 2022). While conjugating unique ligands or antibodies may improve tissue specificity or disease targeting, available natural ligands and target receptor density can be limiting factors to an effective delivery and by changing the chemical or physical makeup can add additional cost and complexity to both formulation and delivery (Cheng et al., 2012; Paunovska et al., 2022). RNA delivery with nanoparticle (NP) such as FDA approved LNPs for RNAi delivery discussed previously and polymer-based systems are also commonly used to improve blood pharmacokinetics (Pitulle et al., 1995; Karra and Benita, 2012; Leung et al., 2012; Leung et al., 2014; FDA, 2018; Boca et al., 2020; Fortere et al., 2020; Paunovska et al., 2022; Smith et al., 2022). For example, in a recently published article researchers implemented a liposome nanoparticle fitted with polymers consisting of six repeats of aspartate, serine and serine ((DSS)₆) that is shown to target bone formation surfaces to enhance the delivery of a casein kinase-2 interacting protein-1 (Ckip-1) mRNA targeting siRNA to osteogenic lineage cells involved in the progression of osteoporosis (Gao et al., 2022). Both in vitro and in vivo findings supported this novel liposome-based osteoanabolic therapy to treat osteoporosis by the payload siRNA (Gao et al., 2022).

By using NP formulation, an RNAi-based drug like patisiran can remain chemically unmodified or to a less degree but protected from degradation by serum RNases (FDA, 2018) (Table 4). However, NP-based formulations can be compromised by non-selective tissue distribution barring them from FDA approval for RNAi delivery (Table 4). Therefore, tissue- or receptor-specific ligands are under investigation and may be incorporated into NPs towards an optimal formulation to enhance target tissue delivery and drug internalization (Johannes and Lucchino,
While an adaptable means of delivery, there is the concern about risk of inducing immunogenic effects by non-natural NPs themselves, beyond the RNAi macromolecules, and the barrier for endosomal escape once endocytosed (Kumar et al., 2015; Lu et al., 2018; Xu et al., 2018). To address these concerns, employing exosome-based delivery offer an alternative to NPs as endogenous vehicles under investigation that can load, protect, and deliver therapeutic RNAs (Kumar et al., 2015; Ha et al., 2016; Barile and Vassalli, 2017; Lu et al., 2018). Exosomes are endogenous extracellular vesicles that play important roles in cell-cell communications and can transfer genetic and biochemical information and fuse with cell membranes to directly deliver cargo into the cytoplasm (Lu et al., 2018). Using exosomes over traditional NPs provides a more advantageous natural means of drug delivery that are hoped to increase delivery, membrane permeation efficiency, and biocompatibility to overcome both immunogenicity and endosomal escape (Alvarez-Erviti et al., 2011; van den Boorn et al., 2011; Shtam et al., 2013; Haney et al., 2015; Ha et al., 2016; Lu et al., 2018; Smith et al., 2022). One example is the exosome-GE11 peptide, a modified exosome with a surface GE11 peptide designed to target the epidermal growth factor receptor (EGFR) to deliver RNAi agents to EGFR-expressing cancer tissues (Ohno et al., 2013). However, the use of exosomes comes with some disadvantages including inefficient or low extraction, and isolation yield as well as exosome encapsulation and loading of hydrophilic molecules and the delivery of unwanted, off-target components inherent in exosome composition providing an opportunity for researchers to investigate and improve exosome
extraction methodology, isolation yield, and loading prior to FDA approval for RNAi delivery (Akuma et al., 2019).

Other methods of RNA delivery under investigation include viral systems to express genes holding their RNAi into desired tissues, inorganic material-based NPs such as gold-, mesoporous silicon-, graphene oxide-, or iron(III) oxide (Fe$_3$O$_4$)-mediated NPs, and polymeric vectors among others (Dowdy, 2017; Fu et al., 2019; Paunovska et al., 2022). Each class of RNA delivery come with both advantages and disadvantages increasing the difficulty of choosing the most appropriate delivery vehicle. Viral systems including adenoviral, adeno-associated viral, retroviral, lentiviral vectors are useful for long-term gene expression by can transfer genes into different target tissues (Fu et al., 2019). However, viral delivery is complicated by the induction of immunogenicity and toxicity as well as a low loading capacity impeding FDA approval for RNAi delivery (Vannucci et al., 2013; Fu et al., 2019) (Table 4). Gold-mediated NPs can interact with thiol and amino functional groups that can be conjugated to RNAi agents to enhance loading and delivery (Chen et al., 2017; Fu et al., 2019; Cai et al., 2020). Mesoporous silica-mediated NPs provide more biocompatible a large, easily modified, and thermodynamically stable surface area (Mamaeva et al., 2013; Fu et al., 2019). Graphene oxide-mediated NPs are contain a unique honeycomb-like network that can absorb a wide array of nucleic acids (Loh et al., 2010; Fu et al., 2019). Fe$_3$O$_4$-mediated NPs can form nanocomplexes with mesoporous magnetic clusters and link with polymeric vectors such as polyethylenimine (PEI) or polyacrylic acid (PAA) to load RNAi agents and increase uptake in vivo (Sun et al., 2017; Fu et al., 2019). However, much like viral based vectors, most non-viral vectors are
limited in current clinical research and lack FDA approved use for RNAi delivery because of their toxicity and potential for off-target delivery (Fu et al., 2019) (Table 4).

In a recent publication, researchers had developed a novel delivery system for miRNA based on in situ self-assembly between gold (Au) salts and tumor suppressor miRNA mimics to form Au-miRNA nanocomplexes (Cai et al., 2020). In this study, in situ self-assembled Au-miRNA nanocomplexes were found not only to be present in cancer cells and to inhibit proliferation in vitro, but also demonstrated tumor suppression and enhanced antitumor effects in sc tumor models in vivo (Cai et al., 2020). Their novel and current work provides supportive evidence for NP delivery strategies to effectively transport large and negatively charged RNA and oligonucleotide molecules cargo. However, the most important aspect in the pursuit of “targeted delivery” is to develop and formulate a drug to improve its pharmacokinetics, pharmacodynamics, and safety profile all while simultaneously maintaining the drugs functionality and, in the case of RNAi, its interactions with endogenous RNAi machinery and intracellular target transcripts at the right level and right time to achieve the right outcomes (Yu et al., 2019; Zhang et al., 2021b).

6. Novel Biotechnologies to Produce RNAi Agents

While chemical and biochemical synthesis remains a consistent means of RNA molecule production, there is a growing concern that these methods introduce changes to the physical and chemical properties of RNAi agents that likely exhibit distinct efficacy and safety profiles from those of naturally synthesized and modified RNA equivalents (Morena et al., 2018; Yu et al.,
2019; Yu et al., 2020a; Yu et al., 2020b). To address these concerns, alternative methods have emerged to steer RNA production back into live cells for natural products. Two genres of *in vivo* RNA production are through direct expression using specific host bacteria strains and RNA production using stable carriers (*Figure 3*).

### 6.1. Direct expression

*In vivo* RNA production by direct expression was initiated by the identification of two bacterial strains, *Rhodovulum sulfidophilum* and an RNase III deficient-*Corynebacterium glutamicum* (Pereira et al., 2017; Hashiro et al., 2019b) (*Figure 3*). *R. sulfidophilum*, is a marine phototrophic bacterium with the capability to efflux nucleic acids but not RNases (Nagao et al., 2015; Pereira et al., 2017; Kikuchi and Umekage, 2018) (*Figure 3*). Such characteristics allow *R. sulfidophilum* to accumulate RNA products in culture medium without fear of nuclease degradation and has shown success in producing a variety of RNA molecules such as tRNAs, rRNAs, aptamers (Ando et al., 2006; Suzuki et al., 2010; Nagao et al., 2014) and human pre-miRNAs (Pereira et al., 2016). RNA accumulated in culture media can be isolated and purified to attain the target RNA molecule (Kikuchi and Umekage, 2018; Yu et al., 2020a) (*Figure 3*). However, direct expression by *R. sulfidophilum* demonstrated a low yield of recombinant RNA production that is likely due to an ineffective diffusion or efflux of RNA into the medium or the presence of intracellular RNases that can readily degrade recombinant RNAs before they can exit the cells and accumulate in medium (Pereira et al., 2017; Kikuchi and Umekage, 2018; Yu et al., 2020a).
Recent exploration into a novel strain of *C. glutamicum* is being studied to produce RNA molecules *in vivo* through direct expression (Hashiro et al., 2019a; Hashiro et al., 2019b) (Figure 3). This particular strain of *C. glutamicum* lacks the RNase III ribonuclease because of a disruption in its encoding gene (2256LΔrnc) (Hashiro et al., 2019a; Hashiro et al., 2019b). Therefore, in combination with a strong promoter driving the overexpression of recombinant RNA, target RNA can be accumulated in RNase III deficient-*C. glutamicum* towards mass production (Hashiro et al., 2019a; Hashiro et al., 2019b) (Figure 3). This novel strain is expected to have direct application to *in vivo* production of biologic RNAs (Yu et al., 2020a).

Another form of direct expression is co-expression of target RNA molecules with protective RNA-binding proteins. Plant RNA virus tombusvirus encoded 19 kD protein (p19) is an RNA-binding protein known to selectively bind and suppress the RNAi function of double-stranded siRNAs with high affinity and it is being implemented today for the isolation, detection, and stabilization of both siRNA and miRNA (Qiu et al., 2002; Silhavy et al., 2002). Through co-expression, siRNA-embedded within an shRNA is designed to be processed by bacterial RNases to target siRNAs and form stable complexes with p19 to avoid degradation (Qiu et al., 2002; Huang et al., 2013). Following co-expression, total protein containing siRNA-p19 complexes can be extracted from bacteria, purified, and the complexes can be dissociated with denaturing agents (e.g., SDS) for the fully processed and protected RNAi agents to be purified (Yu et al., 2020a).

6.2. Using stable carriers
The use of stable carriers offers an alternative to direct expression. There are several stable carriers available to produce recombinant RNA molecules including viroid-derived circRNA carriers, tRNA or rRNA scaffolds, and chimeric tRNA/pre-miRNA carriers. The viroid-derived circRNA carrier is a relatively new form of stable carrier capable of producing large amounts of stable recombinant RNAs in *Escherichia coli* (Daros et al., 2018). Viroids are a special class of infectious agents that contain short, single-stranded circRNAs found in higher plant species (Branch and Robertson, 1984; Branch et al., 1988). The viroid-derived circRNA carrier uses the co-expression of two plasmids to produce and circularize recombinant RNA molecules into viroids (Daros et al., 2018). The first plasmid offers the recombinant RNA-viroid molecule from the eggplant latent viroid (ELVd) to form the pLELVd-BZB plasmid (Daros et al., 2018), and the second plasmid produces the tRNA ligase used for viroid circularization into chimeric circRNA (Daros et al., 2018). The viroid-carrying target RNA can be isolated from bacterial cell lysate and purified by gel electrophoresis or fast protein liquid chromatography (FPLC) methods (Daros et al., 2018).

Another form of stable carriers uses rRNA as a scaffold to produce recombinant RNA molecules in bacteria (Zhang et al., 2009) (Figure 3). As the most abundant species of RNA found in living cells by mass, rRNA-based carriers resembling rRNA exploit endogenous recognition and are capable of accommodating and protecting target RNAs (Zhang et al., 2009). The 5S rRNA is used as a scaffold because of its stability to carry and protect a variety of sRNA molecules with DNAzyme-specific sequences within its stem II and stem III site structures (Pitulle et al., 1995; D'Souza et al., 2003; Zhang et al., 2009; Liu et al., 2010) (Figure 3). By using this stable carrier, a plasmid containing the 5S rRNA-scaffold with an embed target RNA can be overexpressed in
bacteria by rRNA gene promoters, rrnB P1 and P2 and rRNA transcription terminators, rrnB T1 and T2, prior to recombinant RNA isolation and purification from cell lysate (Zhang et al., 2009; Liu et al., 2010). Target RNAs can then be selectively released from their rRNA-scaffold by DNAzyme-mediated recovery (Zhang et al., 2009; Liu et al., 2010).

Compared to rRNA, the tRNA offers a simple scaffold to produce recombinant RNA molecules in bacteria (Ponchon and Dardel, 2007; Ponchon et al., 2009; Nelissen et al., 2012) (Figure 3). tRNA are an endogenous molecule found with high abundance in living cells, the tRNA scaffold uses intracellular recognition of the tRNA structure to carry recombinant RNA for overexpression and accumulation in bacteria (Meinnel et al., 1988; Gaudin et al., 2003). In this design, the tRNA anticodon sequence is replaced with an RNA sequence of interest all while leaving the remainder of the tRNA sequence intact to conserve the recognizable cloverleaf structure and overall stability of the tRNA in vivo (Ponchon and Dardel, 2007) (Figure 3). To implement this stable carrier in vivo, a plasmid containing the recombinant RNA within a tRNA scaffold is overexpressed in E. coli, driven by a murein lipoprotein (lpp) promoter (Ponchon et al., 2009) or T7 promoter (Nelissen et al., 2012), and the overexpressed recombinant RNA is then isolated and purified from cell lysate. The tRNA scaffold has been successfully employed for the design and production of various RNA molecules including viral RNAs and aptamers (Ponchon and Dardel, 2007), pre-miRNAs (Li et al., 2014; Li et al., 2015; Wang et al., 2015), and snoRNAs (Peng et al., 2014).

Recently, a novel hybrid tRNA/pre-miRNA carrier platform has been established for large-scale production of bioengineer RNA agents (BioRNA, previously termed BERA) by in vivo
fermentation with high yield and purity (Chen et al., 2015; Ho et al., 2018; Li et al., 2021; Petrek et al., 2021) (Figure 3). The BioRNA consists of a ssRNA molecule with three major components, a tRNA scaffold linked to a pre-miR-34a sequence with an embedded, interchangeable miRNA duplex. As a result, BioRNA can accommodate a wide variety of target RNAi molecules including RNA aptamers and shRNA as well as miRNA, siRNA, or sRNA along with their complimentary sequence (Ho and Yu, 2016; Yu et al., 2019; Yu et al., 2020a; Yu and Tu, 2022). After introduced into human cells, it is likely that BioRNA enters into endogenous miRNA processing at the pre-miRNA step in the cytoplasm (Domsinska and Dykxhoorn, 2010; Yu et al., 2020a) (Figure 1). However, both canonical processing and selective RNAi agent release (Chen et al., 2015; Ho et al., 2018; Jilek et al., 2019; Tu et al., 2019; Petrek et al., 2021) and Dicer-independent, non-canonical processing (Ho et al., 2018) of BioRNAs have been demonstrated, dependent on the RNAi sequence incorporated into the BioRNA.

In its initial design, BioRNA used a chimeric bacterial methionyl tRNA (btRNA^{Met}) fused with human hsa-pre-miR-34a (btRNA^{Met}/hsa-pre-miR-34a) to determine its capability of overexpression in bacteria (Chen et al., 2015). What separates hybrid BioRNA from tRNA stable carriers is the inclusion of a pre-miR-34a as a critical component designed for effective and natural cleavage, guidance, and incorporation into the RISC complex by endogenous machinery (Li et al., 2021). To improve compatibility in human cells, the BioRNA design was adapted by substituting the bacterial tRNA with human versions (Li et al., 2021). Several human tRNA (htRNA) were screened and identified to efficiently couple with hsa-pre-miR-34a, among them.
seryl (htRNA\textsuperscript{Ser}) and leucyl (htRNA\textsuperscript{Leu}) hRNAs led to an improved overexpressed in \textit{E. coli}, making up over 40% of the total bacterial RNA (Li et al., 2021).

The BioRNA carrier enables recombinant RNA production in live culture to yield more natural RNA molecules (Chen et al., 2015; Ho et al., 2018; Li et al., 2021). To do so, the protein coding sequence the BioRNA construct is cloned into a pBSTNAV vector with a lpp promoter and transformed into \textit{E. coli} for fermentation and overexpression of the recombinant RNA (Li et al., 2021). Total RNA is then extracted from cell lysate and purified by anion exchange FPLC chromatography to yield an BioRNA product with preserved structure, stability, activity, and safety like that of endogenous RNAi molecules (Wang et al., 2015; Ho et al., 2018; Li et al., 2021). The resulting products are high-quality, biologically active RNA molecules that are well tolerated in animal models and resemble the functions of endogenous cellular RNAi mechanisms (Chen et al., 2015; Li et al., 2015; Jian et al., 2017; Jilek et al., 2017; Alegre et al., 2018; Ho et al., 2018; Zhang et al., 2018; Jilek et al., 2019; Li et al., 2019; Tu et al., 2019; Xu et al., 2019; Tu et al., 2020; Umeh-Garcia et al., 2020; Yi et al., 2020; Deng et al., 2021; Li et al., 2021).

7. Conclusions and Perspectives

Since its discovery, evidence suggests that RNAi is an adaptable and versatile tool that can be modified by researchers to study reverse genetics, specific gene repression, and develop targeted therapies. More importantly, the components that make up the RNAi pathway are not a static set of sequential steps but instead an expanding pool of adaptable components that function to deliver gene specific regulation (RNAi Molecules and Mechanisms) (Figure 1). This is evident
in new and developing technologies that use the foundations of RNAi to develop novel synthesis, improve functionality, potency, stability, and pharmacology (Figure 3) as well as establish new methods of delivery (Table 4), and form groundbreaking therapeutic strategies against diseases by acting on previously considered un- or non-druggable targets. This notion is supported in the wake of the fourth therapeutic siRNA to gain approval by the FDA (inclisiran) and are further supported by the numerous RNAi-based therapeutics advancing through clinical trials (Tables 1, 2, and 3). However, with most RNAi therapeutics functioning as siRNA (Tables 1 and 2) or anti-miRs there are few miRNA mimics to made into clinical trials (Table 3). This leaves a vastly untapped market for miRNA replacement therapy. MiRNA has the unique property of targeting several mRNA transcripts and creates an opportunity for a single drug to regulate multiple targets or biological pathways that are often dysregulated in a disease. To achieve this, factors such as dosing, cross-reactivity, on-target efficacy, and unwanted effects need to be addressed through comprehensive basic and clinical research before they can attain regulatory approval.

Efforts continue to be made to bring the production of various RNAi molecules back into the cells and away from chemical modifications by using direct expression in bacteria and the use of stable carriers to preserve these natural properties while continuing to maintain stability, biological activity, and safety, discussed in the (Novel Biotechnologies to Produce RNAi Agents). Among them, the tRNA/pre-miRNA carrier-based platform technology has proven to be a robust and versatile means of harnessing in vivo RNA production of biologically active miRNAs, siRNAs, aptamers, and sRNAs that are designed to recapitulate several of the physical and chemical properties of natural RNA molecules needed for RNAi-based therapy. Future
research exploring the use of bioengineered or recombinant RNAi molecules against chemo-engineered RNA analogs will provide insight and define their efficacy as biochemical candidates for both biological research and as clinical treatments for disease.
Authorship Contributions:

Performed data analyses: G.M. Traber and A.M. Yu

Wrote and contributed to the writing of the manuscript: G.M. Traber and A.M. Yu.
References


Lai CF, Chen CY and Au LC (2013) Comparison between the repression potency of siRNA targeting the coding region and the 3'-untranslated region of mRNA. Biomed Res Int 2013:637850.


Reijman MD, Schweizer A, Peterson ALH, Bruckert E, Stratz C, Defesche JC, Hegele RA and Wiegman A (2022) Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. *Eur J Prev Cardiol*.


of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. *CNS Drugs* **32**:1053-1067.


Footnotes:

This work was supported by the National Institute of General Medical Sciences [R35GM140835] and National Cancer Institute [R01CA225958 and R01CA253230], National Institutes of Health. Gavin M. Traber was supported by a National Institutes of General Medical Sciences-funded Pharmacology Training Program Grant [T32GM099608].

No author has an actual or perceived conflict of interest with the contents of this article.

Send reprint requests to: Dr. Ai-Ming Yu, Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA; Email: aimyu@ucdavis.edu.
Figure Legends

Figure 1. Overview of miRNA biogenesis and functions and siRNA mechanisms of action.
(A) Intragenic or intergenic miRNA genes are transcribed by RNA polymerases II or III into primary miRNA (pri-miRNA; > 1,000 nt) transcripts in canonical pathway (black lines). (B) Pri-miRNAs are subjected to nuclear processing by the microprocessor, Drosha-DGCR8 complex, to release shorter precursor miRNAs (pre-miRNAs) (e.g., ~65 nt). (C) Noncanonical miRNA transcripts (e.g., miRtrons) are derived from the genome and subjected to RNA splicing to form pre-miRNAs independent on the microprocessor (orange lines). (D) Pre-miRNAs are exported into the cytoplasm via Exportin 5 transport complex. (E) In the cytoplasm, pre-miRNAs are processed by Dicer/TRBP complex to form miRNA duplexes (18-25 nt). (F) Dicer-independent production of miRNA duplexes (yellow). (G) The guide strand (blue) of the miRNA duplex is selected and loaded into the RNA-induced silencing complex (RISC) to form the miRNA-RISC complex (miRISC) while the passenger strand (red) is degraded. (H) Functional miRNA binds to the 3’-untranslated region (3’UTR) of targeted mRNA to perform posttranscriptional gene regulation, either to accelerate mRNA cleavage or degradation or repress translation. (I) Exogenous siRNAs can be introduced into cytoplasm through endocytosis or receptor-mediated uptake (green). (J) The antisense strand (blue) is selectively loaded into the RISC to form the siRNA-RISC complex (siRISC) while the sense strand (red) is degraded. (K) Functional siRNA typically acts on the protein coding sequence (CDS) of target transcript to cleave or initiate transcript degradation.
Figure 2. Common actions of four FDA approved siRNA medications in hepatocytes. (A) Patisiran is a double stranded siRNA drug (sense in red, and antisense in blue) formulated in a lipid nanoparticle (LNP) decorated with polyethylene glycol (pegylation) and it is administered intravenously for the treatment of hereditary transthyretin-mediated amyloidosis. The LNP induces an opsonization-based immune response and is endocytosed by the hepatocyte prior to endosomal escape. (B) Givosiran, lumasiran, and inclisiran, in which the sense strand (red) is conjugated with three N-acetylgalactosamine (GalNAc) moieties, are administered sc for the treatments of acute hepatic porphyria, primary hyperoxaluria type 1, and heterozygous familial hypercholesterolemia, respectively. The GalNAc moieties are recognized by asialoglycoprotein receptor 1 (ASGR1), which is highly expressed on the surface of hepatocytes, to facilitate the uptake of siRNAs. (C) The antisense strand (blue) is preferably loaded into the RNA-induced silencing complex (RISC) to form the siRNA-RISC complex (siRISC) while the passenger strand (red) is degraded. (D) Givosiran-derived siRISC binds to the protein coding sequence (CDS) of target mRNA towards cleavage or degradation. (E) Patisiran-, lumasiran-, and inclisiran-derived siRISC interact with the 3'-untranslated regions (3'UTRs) of target mRNAs to achieve gene silencing. (F) SiRNA drugs (givosiran, patisiran, lumasiran, and inclisiran) target specific mRNAs to achieve control of their respective diseases. Abbreviations: AHP, acute hepatic porphyria; ALAS1, aminolevulinate synthase 1; HAO1, hydroxyacid oxidase 1; hATTR, hereditary transthyretin-mediated amyloidosis; HeFH, heterozygous familial hypercholesterolemia; PCSK9, proprotein convertase subtilisin/kexin type 9; PH1, primary hyperoxaluria type 1; TTR, transthyretin.
Figure 3. Novel biotechnologies to produce RNAi agents. (A) Direct expression is one class of novel RNAi agent production. Two forms of direct expression make use of two bacterial strains, *Rhodovulum sulfidophilum* and an RNase III deficient-*Corynebacterium glutamicum*. The marine phototropic bacterium *R. sulfidophilum* has the capability to efflux oligonucleotides such as RNA but not RNases. These characteristics allow researchers to transform *R. sulfidophilum* with an RNA-expressing plasmid to directly express the target RNA followed by efflux and accumulate in RNase-free culture media and can be isolated and purified to attain the target RNA molecule. A novel strain of *C. glutamicum* containing a mutation in the RNase III gene (2256LΔrnc) and provides an RNAse III ribonuclease-free bacterium for RNA accumulation. Target RNA may be directly expressed and accumulated in *C. glutamicum* free from RNase degradation for later isolation from cell lysate and purification. (B) The use of stable carriers constitutes a second class of novel RNAi agent production. Transfer RNA (tRNA) and ribosomal RNA (rRNA) can each function as stable RNA scaffolds. By retaining structures and sequences of these highly abundant RNA classes, target RNA is expected to exploit endogenous recognition and accumulate within bacteria. As most recombinant RNAs cannot be overexpressed with tRNA or rRNA scaffold, specific hybrid tRNA/pre-miRNA molecules showing high-level expression in *E. coli* has been identified, developed, and proven as unique carriers to effectively accommodate a wide variety of target RNAi molecules including RNA aptamers, miRNAs, siRNAs, or sRNA along with their complimentary sequences for high-yield and large-scale production of biologic RNAi agents.
Table 1. FDA approved siRNA medications. Abbreviations: A, adenosine; Af, adenine 2'-F ribonucleoside; AHP, acute hepatic porphyria; ALAS1, aminolevulinate synthase 1; Am, adenine 2'-OMe ribonucleoside; ASCVD, atherosclerotic cardiovascular disease; C, cytidine; Cf, cytosine 2'-F ribonucleoside; Cm, cytosine 2'-OMe ribonucleoside; dT, thymidine; G, guanosine; Gf, guanine 2'-F ribonucleoside; Gm, guanine 2'-OMe ribonucleoside; HAO1, hydroxycacid oxidase 1; hATTR, hereditary transthyretin-mediated amyloidosis; HeFH, heterozygous familial hypercholesterolemia; L96, tri-N-acetylgalactosamine; PCSK9, proprotein convertase subtilisin/kexin type 9; PH1, primary hyperoxaluria type 1; s, phosphorothioate; TTR, transthyretin; U, uracil; Uf, uracil 2'-F ribonucleoside; Um, uracil 2'-OMe ribonucleoside.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Chemistry</th>
<th>Target</th>
<th>Disease</th>
<th>FDA Approval</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patisiran</td>
<td>Sense: 5'-GUmAACmCmAAGAGUmAUmUmCmAUmTdT-3' Antisense: 3'-dTdTCAUmUGGUUCUCACUmAAGGU-5'</td>
<td>TTR</td>
<td>hATTR</td>
<td>2018</td>
<td>(FDA, 2018)</td>
</tr>
<tr>
<td>Givosiran</td>
<td>Sense: 5'-CmsAmsGmAmAmGfAmGfUmGfUmCfUmCmUmCmUmAmL96-3' Antisense: 3'-UmGsGmUfCmUfCmAfCmAfGmGmGfAfAfAsAsUms-3'</td>
<td>ALAS1</td>
<td>AHP</td>
<td>2019</td>
<td>(FDA, 2019)</td>
</tr>
<tr>
<td>Lumasiran</td>
<td>Sense: 5'-GmsAmsCmUmCmCfCfUmGmGmAmAmAmAmAmAmAmL96-3' Antisense: 3'-AmsCmCmUmGmAmAfGmUfAmGmGmCfCfUmUmUmsAsAs-3'</td>
<td>HAO1</td>
<td>PH1</td>
<td>2020</td>
<td>(FDA, 2020)</td>
</tr>
<tr>
<td>Inclisiran</td>
<td>Sense: 5'-CmsUmsAmGmAmCmCfGmUmdTUmUmGmUmUmUmGmUmL96-3' Antisense: 3'-UmsAmsGmAmsCmUmCfGmAmsAfAmAmAfAmCfGmAmsAfAsCfsAmsAm-3'</td>
<td>PCSK9</td>
<td>HeFH and ASCVD</td>
<td>2021</td>
<td>(FDA, 2021)</td>
</tr>
</tbody>
</table>
Table 2. **Therapeutic siRNAs in clinical trials.** Abbreviations: ACC, adrenocortical carcinoma; AKI, acute kidney injury; DED, dry eye disease; AMD, age-related macular degeneration; ARF, acute renal failure; CNV, choroidal neovascularization; DGF, delayed graft function; DME, diabetic macular edema; DR, diabetic retinopathy; hATTR, hereditary transthyretin-mediated amyloidosis; HCC, hepatocellular carcinoma; NAION, non-arteritic anterior ischemic optic neuropathy; PDAC, pancreatic ductal adenocarcinoma; PDC, pancreatic ductal carcinoma.

<table>
<thead>
<tr>
<th>Product</th>
<th>Sponsor Company</th>
<th>Target</th>
<th>Disease</th>
<th>Current Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fitusiran (ALN-AT3SC)</td>
<td>Sanofi Genzyme</td>
<td>Antithrombin</td>
<td>Hemophilia A &amp; B</td>
<td>Phase III – NCT03417245 (ATLAS-A/B)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase III – NCT03417102 (ATLAS-INH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase III – NCT03549871 (ATLAS-PPX)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II/III – NCT03974113 (ATLAS-PEDS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase III – NCT03754790 (ATLAS-OLE)</td>
</tr>
<tr>
<td>Nedosiran (DCR-PHXC)</td>
<td>Dicerna Pharmaceuticals</td>
<td>Hepatic LDH</td>
<td>Primary Hyperoxaluria</td>
<td>Phase III – NCT04042402 (PHYOX3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase II – NCT05001269 (PHYOX8)</td>
</tr>
<tr>
<td>Teprasiran (QPI-1002)</td>
<td>Quark Pharmaceuticals</td>
<td>p53</td>
<td>AKI</td>
<td>Phase III – NCT02610296 (ReGIFT)</td>
</tr>
<tr>
<td>Tivanisiran (SYL-1001)</td>
<td>Sylentis S.A.</td>
<td>Transient Receptor Potential Cation Channel Subfamily V member 1</td>
<td>Ocular Pain and DED</td>
<td>Phase III – NCT03108664 (HELIX)</td>
</tr>
<tr>
<td>Vutrisiran (ALN-TTRSC02)</td>
<td>Alnylam Pharmaceuticals</td>
<td>Transthyretin</td>
<td>hATTR</td>
<td>Phase III – NCT03759379 (HELIOS-A)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phase III – NCT04153149 (HELIOS-B)</td>
</tr>
<tr>
<td>Cosdosiran (QPI-1002)</td>
<td>Quark Pharmaceuticals</td>
<td>Caspase-2</td>
<td>NAION</td>
<td>Phase II/III (Terminated) - NCT02341560</td>
</tr>
<tr>
<td>ID</td>
<td>Company</td>
<td>Target Protein</td>
<td>Clinical Trial Details</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------</td>
<td>----------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>AGN211745</td>
<td>Allergan</td>
<td>VEGFR1</td>
<td>CNV and AMD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I/II - NCT00363714</td>
<td></td>
</tr>
<tr>
<td>PF-04523655</td>
<td>Quark Pharmaceuticals</td>
<td>VEGFR1</td>
<td>AMD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phases I - NCT00725686</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AMD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase II - NCT00713518</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CNV, RN, and DME</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase II - NCT01445899</td>
<td></td>
</tr>
<tr>
<td>siG12D LODER</td>
<td>Silenseed Ltd</td>
<td>KRASG12D</td>
<td>PDAC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I - NCT01188785</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase II - NCT01676259</td>
<td></td>
</tr>
<tr>
<td>TKM-080301</td>
<td>Arbutus Biopharma Corp.</td>
<td>PLK1</td>
<td>HCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I/II - NCT02191878</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroendocrine Tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>and ACC</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I/II - NCT01262235</td>
<td></td>
</tr>
<tr>
<td>Atu027</td>
<td>Silence Therapeutics Gmbh</td>
<td>Protein Kinase N3</td>
<td>Advanced Solid Tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I - NCT00938574</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PCD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phases I/II - NCT01808638</td>
<td></td>
</tr>
<tr>
<td>TD101</td>
<td>Pachyonychia Congenita Project</td>
<td>KRT6A</td>
<td>Pachyonychia congenita</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I - NCT00716014</td>
<td></td>
</tr>
<tr>
<td>ARC-520</td>
<td>Arrowhead Pharmaceuticals</td>
<td>cccDNA-derived viral mRNA</td>
<td>Safety/Tolerability in Healthy Volunteers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I - NCT01872065</td>
<td></td>
</tr>
<tr>
<td>QPI-1002</td>
<td>Quark Pharmaceuticals</td>
<td>p53</td>
<td>ARF and AKI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phase I - NCT00554359</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DGF and Complications of Kidney Transplant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phases I/II - NCT00802347</td>
<td></td>
</tr>
</tbody>
</table>

This article has not been copyedited and formatted. The final version may differ from this version.
Table 3. MiRNA-based therapies in clinical and preclinical investigations. Abbreviations: AHF, acute heart failure; ARBCP, abnormal red blood cell production; CHF, chronic heart failure; CMD, cardiometabolic disease; MPM, malignant pleural mesothelioma; MI, Myocardial Infarction; NAFLD, nonalcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NSCLC, non-small cell lung cancer; PAD, peripheral arterial disease; PKD, polycystic kidney disease; PLC, primary liver cancer; RCC, renal cell carcinoma; SCLC, small cell lung cancer.

<table>
<thead>
<tr>
<th>Product</th>
<th>Sponsor company</th>
<th>miRNA</th>
<th>Disease</th>
<th>Current Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miravirsen (SPC3649)</td>
<td>Roche/Santaris</td>
<td>Anti-miR-122</td>
<td>Hepatitis C</td>
<td>Phase II - NCT01727934, NCT01872936, NCT01200420</td>
</tr>
<tr>
<td>CDR132L</td>
<td>Cardior Pharmaceuticals GmbH</td>
<td>Anti-miR-132</td>
<td>MI and AHF (Left Sided)</td>
<td>Phase II - NCT05350969</td>
</tr>
<tr>
<td>Lademirsen</td>
<td>Sanofi Genzyme</td>
<td>Anti-miR-21</td>
<td>Alport syndrome</td>
<td>Phase I - NCT03373786</td>
</tr>
<tr>
<td>AZD4076 (RG-125)</td>
<td>AstraZeneca</td>
<td>Anti-miR-103/107</td>
<td>NAFLD</td>
<td>Phase I - NCT02826525</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NASH</td>
<td>Phase I - NCT02612662</td>
</tr>
<tr>
<td>RGLS4326</td>
<td>Regulus Therapeutics</td>
<td>Anti-miR-17</td>
<td>PKD</td>
<td>Phase I - NCT04536688</td>
</tr>
<tr>
<td>TargomiRs</td>
<td>Asbestos Diseases Research Foundation</td>
<td>miR-16 mimic</td>
<td>MPM and NSCLC</td>
<td>Phase I - NCT02369198</td>
</tr>
<tr>
<td>MRX34</td>
<td>Mirna Therapeutics</td>
<td>miR-34 mimic</td>
<td>Melanoma</td>
<td>Phase I/II (Withdrawn) - NCT02862145</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PLC, SCLC, Lymphoma, Melanoma, Multiple Myeloma, RCC, and NSCLC</td>
<td>Phase I ( TERMINATED) - NCT01829971</td>
</tr>
<tr>
<td>Remlarsen (MRG-201)</td>
<td></td>
<td>miR-29 mimic</td>
<td>Keloid</td>
<td>Phase II - NCT02603224, NCT03601052</td>
</tr>
<tr>
<td>MRG-110</td>
<td>MiRagen Therapeutics/Viridian</td>
<td>Anti-miR-92a</td>
<td>Angiogenesis / Ischemia</td>
<td>Phase I - NCT03603431</td>
</tr>
<tr>
<td>MRG-107</td>
<td></td>
<td>Anti-miR-155</td>
<td>Atherosclerosis</td>
<td>Preclinical</td>
</tr>
<tr>
<td>MGN-1374</td>
<td></td>
<td>Anti-miR-15 and Anti-miR-195</td>
<td>Post-Myocardial Infarction</td>
<td>Preclinical</td>
</tr>
<tr>
<td>MGN-2677</td>
<td>Anti-miR-143/145</td>
<td>Vascular Disease</td>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------</td>
<td>-----------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>MGN-4220</td>
<td>Anti-miR-29</td>
<td>Cardiac Fibrosis</td>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td>MGN-4893</td>
<td>Anti-miR-451</td>
<td>ARBCP – like disorders</td>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td>MGN-5804</td>
<td>Anti-miR-378</td>
<td>CMD</td>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td>MGN-6114</td>
<td>Anti-miR-92</td>
<td>PAD</td>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td>MGN-9103</td>
<td>Anti-miR-208</td>
<td>CHF</td>
<td>Preclinical</td>
<td></td>
</tr>
</tbody>
</table>
Table 4. Non-viral systems and vehicles for the delivery of RNAi therapeutics.

Abbreviations: ELV, exosome-like vesicle; DSPC, [1,2-distearoyl-sn-glycero-3-phosphocholine]; Fe$_3$O$_4$, Iron(III) oxide; LNP, lipid nanoparticle; NP, nanoparticle; PACE, poly(amine-co-ester); PEG, polyethylene glycol; PEI, polyethylenimine; tri-GalNAc, tri-N-acetylgalactosamine.

<table>
<thead>
<tr>
<th>RNAi Delivery Means</th>
<th>System Composition</th>
<th>FDA Approved RNAi Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ribonucleoside modifications</td>
<td>Adenine 2'-F ribonucleoside</td>
<td>Yes – Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Adenine 2'-OMe ribonucleoside</td>
<td>Yes – Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Cytosine 2'-F ribonucleoside</td>
<td>Yes – Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Cytosine 2'-OMe ribonucleoside</td>
<td>Yes – Patisiran; Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Guanine 2'-F ribonucleoside</td>
<td>Yes – Givosiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Guanine 2'-OMe ribonucleoside</td>
<td>Yes – Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Thymidine</td>
<td>Yes – Patisiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Uracil 2'-F ribonucleoside</td>
<td>Yes – Givosiran; Lumasiran</td>
</tr>
<tr>
<td></td>
<td>Uracil 2'-OMe ribonucleoside</td>
<td>Yes – Patisiran; Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td>Phosphate linkage modifications</td>
<td>Phosphorothioate</td>
<td>Yes – Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td></td>
<td>Charge-neutralizing phosphotriester</td>
<td>No</td>
</tr>
<tr>
<td>Receptor ligand conjugates</td>
<td>Tri-GalNAc</td>
<td>Yes – Givosiran; Lumasiran; Inclisiran</td>
</tr>
<tr>
<td>Antibody conjugates</td>
<td>Entire Antibody</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Antibody fragment</td>
<td>No</td>
</tr>
<tr>
<td>LNP</td>
<td>DSPC</td>
<td>Yes – Patisiran</td>
</tr>
<tr>
<td></td>
<td>PEG-lipids</td>
<td>Yes – Patisiran</td>
</tr>
<tr>
<td></td>
<td>Ionizable</td>
<td>Yes – Patisiran</td>
</tr>
<tr>
<td>Polymer-based NP</td>
<td>PEI</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>PEI-PEG</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Polyurethane</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>PACE</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Micelle</td>
<td>No</td>
</tr>
<tr>
<td>Inorganic material-based NP</td>
<td>Gold-mediated</td>
<td>No</td>
</tr>
<tr>
<td>Material</td>
<td>Charge</td>
<td>Coating Status</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Mesoporous silicon</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Graphene oxide-mediated</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Fe$_3$O$_4$-mediated</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td><strong>Liposome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutral</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Cationic</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>pH-sensitive cationic</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Ionizable</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Chemotherapeutic coated</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td><strong>Exosome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exosome</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Exosome-GE11 peptide</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>ELV</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1
### Figure 2

#### A. Patisiran

- siRNA
- LNP
- Extracellular
- Endosome

#### B. Givosiran, Lumasiran, Inclisiran

- siRNA
- GalNAc
- Hepatocyte
- Endosome

#### C. siRISC

- mRNA
- CDS
- 3’-UTR

#### D. Givosiran

- siRISC

#### E. Patisiran, Lumasiran, Inclisiran

- siRISC

#### F. Patisiran, Givosiran, Lumasiran, Inclisiran

- TTR
- ALAS1
- HAO1
- PCSK9
- Control of Disease hATTR
- Control of Disease AHP
- Control of Disease PH1
- Control of Disease HeFH / ASCVD (with maximal statin therapy)
Figure 3

A. Direct Expression

- **R. sulfidophilum**
  - RNase III deficient

- **C. glutamicum**
  - RNase III 22S6Δrnc

B. Stable Carrier

- tRNA or 5S rRNA
- Hybrid tRNA/pre-miRNA

**Sources:**
- Live Culture Media
- Cell Lysate
- DNA Plasmid
- E. Coli